



Morbidity and Mortality Weekly Report

Weekly

December 8, 2006 / Vol. 55 / No. 48

National Drunk and Drugged Driving Prevention Month — December 2006

December has been designated National Drunk and Drugged Driving Prevention Month (3D Month). 3D Month is supported by public and private-sector organizations committed to preventing crashes caused by impaired drivers.

In 2005, a total of 43,443 traffic fatalities occurred, 39% (16,885) of which were alcohol related (1). Among these alcohol-related fatalities, 86% (14,539) involved at least one driver, pedestrian, or bicyclist with a blood alcohol concentration (BAC) \geq 0.08 g/dL, a level that is illegal in all states. Including both fatalities and persons who survived the crash, the percentage of persons with a BAC ≥0.08 g/dL was 32% for pedestrians, 27% for motorcycle operators, 22% for passenger-car drivers, and 21% for drivers of light trucks. Male drivers and drivers aged 21-24 years had the highest BACs. A previous conviction for driving while impaired had been recorded for 9% of drivers with BACs ≥0.08 g/dL who were involved in fatal crashes, and 25% had had their licenses suspended or revoked previously. Safety belts were used by only 28% of fatally injured drivers with BACs ≥0.08 g/dL, compared with 56% of fatally injured drivers with BACs of 0.00 g/dL.

A program planner, which contains sample publicservice announcements, media tool kits, and program guidance for 3D Month, is available from the National Highway Traffic Safety Administration at http:// www.stopimpaireddriving.org.

Reference

1. National Highway Traffic Safety Administration. Traffic safety facts, 2005 data: alcohol. Washington, DC: National Highway Traffic Safety Administration; 2006. DOT HS 810 616. Available at http://www-nrd.nhtsa.dot.gov/pdf/nrd-30/ncsa/tsf2005/2005tsf/810_616/images/alcohol.pdf.

Alcohol and Other Drug Use Among Victims of Motor-Vehicle Crashes — West Virginia, 2004–2005

Alcohol use is a well-established risk factor for motorvehicle crashes (1). In 2005, approximately 39% of all traffic fatalities in the United States were alcohol related (2). Evidence of driver impairment from use of drugs other than alcohol is less definitive. In 2005, an estimated 4.3% of persons in the United States reported driving under the influence of a drug used recreationally during the preceding year, and an unknown percentage drove while impaired by drugs being used for medical reasons (3). To measure the prevalence of alcohol and drug use among persons killed in motor-vehicle crashes in West Virginia (where test results were available for >80% of fatalities), CDC analyzed 2004 and 2005 data reported by the West Virginia Office of the Chief Medical Examiner (OCME) to the Fatality Analysis Reporting System (FARS) of the National Highway Traffic Safety Administration (NHTSA). This report summarizes the results of that analysis, which determined that the prevalence of drug use (25.8%) was similar to the prevalence of a blood alcohol concentration (BAC) ≥0.08 g/dL (27.7%) among persons killed in motor-vehicle crashes. These results suggest that drug use contributes substantially to driver impairment in West Virginia. Measuring the magnitude of this problem nationally will require better surveillance data. Both surveillance and the development of prevention measures are hampered by difficulties in quantifying and defining drug impairment.

INSIDE

1296 Gastrointestinal Injuries from Magnet Ingestion in Children — United States, 2003–2006

1300 Environmental Barriers to Health Care Among Persons with Disabilities — Los Angeles County, California, 2002–2003

1305 QuickStats

The MMWR series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

Suggested Citation: Centers for Disease Control and Prevention. [Article title]. MMWR 2006;55:[inclusive page numbers].

Centers for Disease Control and Prevention

Julie L. Gerberding, MD, MPH Director

Tanja Popovic, MD, PhD (Acting) Chief Science Officer

James W. Stephens, PhD (Acting) Associate Director for Science

Steven L. Solomon, MD

Director, Coordinating Center for Health Information and Service

Jay M. Bernhardt, PhD, MPH

Director, National Center for Health Marketing

Judith R. Aguilar

(Acting) Director, Division of Health Information Dissemination (Proposed)

Editorial and Production Staff

John S. Moran, MD, MPH (Acting) Editor, MMWR Series

Suzanne M. Hewitt, MPA Managing Editor, MMWR Series

Douglas W. Weatherwax

Douglas W. Weatherwax (Acting) Lead Technical Writer-Editor

Catherine H. Bricker, MS Jude C. Rutledge Writers-Editors

Beverly J. Holland Lead Visual Information Specialist

Lynda G. Cupell Malbea A. LaPete Visual Information Specialists

Quang M. Doan, MBA Erica R. Shaver Information Technology Specialists

Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman Virginia A. Caine, MD, Indianapolis, IN David W. Fleming, MD, Seattle, WA William E. Halperin, MD, DrPH, MPH, Newark, NJ Margaret A. Hamburg, MD, Washington, DC King K. Holmes, MD, PhD, Seattle, WA Deborah Holtzman, PhD, Atlanta, GA John K. Iglehart, Bethesda, MD Dennis G. Maki, MD, Madison, WI Sue Mallonee, MPH, Oklahoma City, OK Stanley A. Plotkin, MD, Doylestown, PA Patricia Quinlisk, MD, MPH, Des Moines, IA Patrick L. Remington, MD, MPH, Madison, WI Barbara K. Rimer, DrPH, Chapel Hill, NC John V. Rullan, MD, MPH, San Juan, PR Anne Schuchat, MD, Atlanta, GA Dixie E. Snider, MD, MPH, Atlanta, GA John W. Ward, MD, Atlanta, GA

FARS is an active, nationwide, population-based surveillance system for motor-vehicle crashes that occur on public roadways and result in the death of a road user (e.g., driver, passenger, pedestrian, or bicyclist) within 30 days (4). FARS draws on law enforcement records, which include the results of alcohol and drug tests performed on persons killed in these crashes. In 2005, drug test results were available for fewer than half of all fatalities in FARS. However, in West Virginia, OCME routinely screens all victims of motor-vehicle fatalities for evidence of impairment from alcohol and licit and illicit drugs, including narcotics (e.g., heroin and opioid analgesics), marijuana, stimulants (e.g., cocaine and amphetamines), depressants (e.g., benzodiazepines and barbiturates), and other licit drugs (e.g., antidepressants and antihistamines) that might impair a road user. OCME confirms positive screening tests with gas chromatography/mass spectrometry testing. If multiple drugs are reported, FARS records up to three drugs based on the following priority order: 1) narcotics, 2) depressants, 3) stimulants, 4) marijuana, and 5) other licit drugs. Drugs administered to decedents by emergency medical service providers are not included. Results of hospital toxicology screenings performed on specimens before death are not included in FARS data from West Virginia unless no other valid postmortem specimen is available.

In 2004 and 2005, a total of 784 motor-vehicle fatalities resulted from crashes on public roads in West Virginia. Of these, 663 (84.6%) had alcohol test results, 660 (84.2%) had drug test results, and 658 (83.9%) had both. Those not tested were typically persons who did not have a valid antemortem sample available and survived too long after the crash for valid postmortem toxicologic testing. Among all drug tests, 78.6% were conducted on blood or both blood and urine. Nearly all of the remaining tests were urine tests only.

OCME detected alcohol in 32.5% of decedents tested for both alcohol and drugs (Table 1). Illegal BACs (≥0.08 g/dL) were detected in 27.7% of decedents, and BACs ranging from 0.01 to 0.07 g/dL were detected in 4.9%. The prevalence of detectable blood alcohol was higher in males and highest among persons aged 16–34 years. Drivers were more likely to have detectable blood alcohol levels than passengers.

Detectable levels of at least one drug were reported for 170 (25.8%) decedents. Of these, 149 (87.6%) had positive blood tests, and 21 (12.4%) had positive urine tests. The prevalence of detectable drug levels was higher in males and highest among persons aged 35–54 years. Drivers were more likely to have detectable drug levels than passengers. Among women and persons aged \geq 55 years, drugs were more prevalent than alcohol. Nearly half (47.3%) of all decedents had alcohol or drugs in their bodies; 11.1% had both. Among decedents with detectable blood alcohol levels, 34.1% tested positive for drugs.

TABLE 1. Percentage of persons killed in motor-vehicle crashes who had positive alcohol or drug tests,* by sex, age group, and type of road user — West Virginia, 2004–2005

		Decede	nts testin	g positiv	e (%)
Characteristic	No.	Alcohol†	One or more drugs§	Alcohol and drugs	Alcohol or drugs
Sex					
Male	463	39.3	27.2	13.4	53.1
Female	195	16.4	22.6	5.6	33.3
Age group (yrs)¶					
<16	30	20.0	6.7	3.3	23.3
16-34	271	41.7	26.2	11.8	56.1
35-54	214	37.4	36.4	16.8	57.0
<u>≥</u> 55	142	9.9	13.4	2.8	20.4
Type of road user					
Driver	458	33.8	28.4	12.2	50.0
Passenger	150	26.7	19.3	8.0	38.0
Pedestrian	42	35.7	16.7	7.1	45.2
Other**	8	50.0	50.0	25.0	75.0
Total	658	32.5	25.8	11.1	47.3

^{*} Restricted to 658 decedents with both alcohol and drug test results.

Among decedents with no detectable blood alcohol levels, 21.8% tested positive for drugs.

Opioid analgesics and depressants were each found in 7.3% of tested decedents (Table 2). The three most common opioid analgesics were hydrocodone, oxycodone, and methadone. The depressants reported were sedatives and muscle relaxants, of which benzodiazepines accounted for 83.3%. The most common benzodiazepines were diazepam and alprazolam. Methamphetamines were involved in four of the five amphetamine reports. Overall, 7.6% of decedents and 9.0% of drivers had two or more of the five different types of drugs in their bodies.

Reported by: J Kaplan, MD, J Kraner, PhD, West Virginia Office of the Chief Medical Examiner. L Paulozzi, MD, Div of Unintentional Injury Prevention, National Center for Injury Prevention and Control, CDC.

Editorial Note: The effects of drugs other than alcohol on drivers have been studied by laboratory testing of volunteers and epidemiologic studies comparing drug-positive and drugnegative drivers after crashes (5–8). Results vary by type of drug. Laboratory studies suggest marijuana and benzodiazepines impair driving performance, but the results of studies of crashes are inconsistent. Persons who are new users of opioid analgesics likely have impaired driving skills, but the low prevalence of opioids among drivers in previous crash studies has made their association with crash responsibility difficult to study. Evidence that stimulants impair driving performance is inconsistent. New users, occasional users, and persons who

TABLE 2. Number and percentage of persons killed in motorvehicle crashes who had positive drug tests,* by type of road user and type of drug — West Virginia, 2004–2005

		Ту	pe of r	oad use	r	
		river = 458)	_	ther = 202)		otal = 660)
Type of drug	No.	(%)	No.	(%)	No.	(%)
Opioid analgesics	36	(7.9)	12	(5.9)	48	(7.3)
Hydrocodone	13	(2.8)	3	(1.5)	16	(2.4)
Oxycodone	9	(2.0)	4	(1.9)	13	(2.0)
Methadone	7	(1.5)	3	(1.5)	10	(1.5)
All others	15	(3.3)	3	(1.5)	18	(2.7)
Depressants	36	(7.9)	12	(5.9)	48	(7.3)
Benzodiazepines	30	(6.6)	7	(3.5)	37	(5.6)
Barbiturates	6	(1.3)	5	(2.5)	11	(1.7)
Meprobamate/						
Carisoprodol	3	(0.6)	0	(0.0)	3	(0.5)
Stimulants	25	(5.4)	7	(3.5)	32	(4.8)
Cocaine or its						
metabolites	20	(4.4)	7	(3.5)	27	(4.1)
Amphetamines	5	(1.1)	0	(0.0)	5	(8.0)
Marijuana	39	(8.5)	9	(4.4)	48	(7.3)
Other licit drugs†	43	(9.4)	10	(5.0)	53	(8.0)
One or more types of drugs	130	(28.4)	41	(20.3)	171	(25.9)
Two or more types of drugs	41	(9.0)	9	(4.4)	50	(7.6)

^{*} Restricted to 660 decedents with drug test results.

have increased their doses of drugs generally are more impaired than persons who have become tolerant of drugs through steady use, such as persons taking drugs daily as prescribed. Both combining alcohol with drugs and use of multiple drugs increase the risk for crashes.

The percentage of drug-positive drivers typically is lower than the percentage of alcohol-positive drivers in U.S. studies of motor-vehicle crashes (6). Recent reviews indicate that 5%–25% of drivers involved in motor-vehicle crashes have positive drug tests (5–7). An NHTSA study of U.S. motor-vehicle crashes during 1990–1991 determined that drugs were involved in 17.8% of driver fatalities (9). Marijuana has been the most common drug found in such studies of fatally injured drivers in North America, followed by cocaine, benzodiazepines, and amphetamines (6). This report differs from previous reports in terms of the relatively high prevalence of drugs among drivers in West Virginia and the finding that prescription drugs (e.g., opioid analgesics and depressants) were more prevalent than illicit drugs. In certain demographic groups of decedents, drugs were more prevalent than alcohol.

The findings in West Virginia cannot be extrapolated to the entire United States because of possible local differences in alcohol or drug use patterns. However, these results might reflect recent nationwide growth in the volume of prescriptions for opioid analgesics and other potentially

[†] Defined as a blood alcohol concentration ≥0.01 g/dL.

[§] Including both licit and illicit drugs (e.g., narcotics, stimulants, marijuana, and depressants) that might impair a road user.

[¶] Age of one decedent was unknown.

^{**} Includes five bicyclists and three persons of unknown type.

Includes drugs that might impair a road user (e.g., antidepressants and antihistamines).

impairing medications. Such drugs are at times taken in combination or with alcohol. In an average week, at least 25% of U.S. adults take five or more prescription or over-the-counter drugs, and 7% take five or more prescription drugs (10). These results might also reflect a recent increase in abuse of prescription drugs; the number of U.S. persons who started recreational use of opioid analgesics, sedatives, and tranquilizers in the previous year increased substantially from 1990 to 2003 (3).

The findings in this report are subject to at least four limitations. First, FARS drug data lack detail; they do not describe the degree of intoxication, the type of use (medical or recreational), or the decedent's familiarity with the drug. Second, detection of a drug in a urine test might reflect previous drug use rather than use at the time of the crash. Third, the involvement of some types of drugs might have been underestimated because FARS captures data on only three drugs. Finally, this study can only estimate the contribution of drug and alcohol impairment to motor-vehicle crash mortality because some impaired drivers who died might not have been responsible for their crashes and because impaired drivers who survived crashes that killed other road users were not included.

Enforcement has been the primary approach to drugimpaired driving. However, enforcement has been hampered by technical challenges to performing sophisticated forensic testing in the field, difficulties obtaining laboratory results in time for legal proceedings, and lack of consensus on which levels or combinations of drugs constitute impairment. In addition, most states do not apply additional penalties for using drugs in combination with alcohol, so limited incentive exists to pay for drug tests in alcohol-impaired drivers (6). These problems also explain the incomplete data on drug use in FARS and the difficulties of performing epidemiologic studies of the crash risks from drugs. Given the changing patterns of drug use in the United States, especially the increased use and abuse of prescription drugs, annual testing of a representative sample of U.S. traffic fatalities for drug use should be considered. This sample might provide the basis for additional studies of the crash risk associated with specific types of drugs.

References

- 1. Ogden EJ, Moskowitz H. Effects of alcohol and other drugs on driver performance. Traffic Inj Prev 2004;5:185–98.
- National Highway Traffic Safety Administration. Traffic safety facts, 2005 data: alcohol. Washington, DC: National Highway Traffic Safety Administration; 2006. DOT HS 810 616. Available at http://www-nrd.nhtsa.dot.gov/pdf/nrd-30/ncsa/tsf2005/2005tsf/810_616/images/alcohol.pdf.
- 3. Substance Abuse and Mental Health Services Administration. Results from the 2004 National Survey on Drug Use and Health: national findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2005. SMA 05-4062. Available at http://www.drugabusestatistics.samhsa.gov.

- 4. National Highway Traffic Safety Administration. Fatality Analysis Reporting System. Available at http://www-nrd.nhtsa.dot.gov/departments/nrd-30/ncsa/FARS.html.
- 5. Kelly E, Darke S, Ross J. A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions. Drug Alcohol Rev 2004;23:319–44.
- Jones RK, Shinar D, Walsh JM. State of knowledge of drug-impaired driving. Washington, DC: National Highway Traffic Safety Administration; 2003. DOT HS 809 642. Available at http://www.nhtsa.dot.gov/ people/injury/research/stateofknwlegedrugs/stateofknwlegedrugs.
- 7. Walsh JM, De Gier JJ, Christopherson AS, Verstraete AG. Drugs and driving. Traffic Inj Prev 2004;5:241–53.
- Couper FJ, Logan BK. Drugs and human performance fact sheets. Washington, DC: National Highway Traffic Safety Administration; 2004. DOT HS 809 725. Available at http://www.nhtsa.gov/people/injury/research/job185drugs/drugs_web.pdf.
- Terhune KW, Ippolito CA, Hendricks DL, et al. The incidence and role of drugs in fatally injured drivers. Washington, DC: National Highway Traffic Safety Administration; 1992. DOT HS 808 065.
- Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States. JAMA 2002;287:337–44.


Gastrointestinal Injuries from Magnet Ingestion in Children — United States, 2003–2006

Ingestion of nonfood objects, inadvertently or intentionally, is common among young children and also occurs with older children and adolescents (1-3). Unless the objects are large or sharp, they usually pass through a child's digestive system without health consequences. However, the Consumer Product Safety Commission (CPSC) has become aware of toy products containing small, powerful rare-earth magnets* that pose unique health hazards to children (4,5). Since 2003, CPSC staff members have identified one death resulting from ingestion of these magnets and 19 other cases of injuries requiring gastrointestinal surgery. This report describes three selected cases and summarizes the 20 cases of magnet ingestion identified by CPSC that occurred during 2003-2006. Caregivers should keep small magnets away from young children and be aware of the unique risks (e.g., volvulus and bowel perforation) (Figure 1) that magnets pose if ingested. When evaluating children who have ingested objects, health-care providers should be aware of potential complications if magnets might be involved.

CPSC and the respective manufacturers announced voluntary recalls of Magnetix magnetic building sets by Rose Art Industries, Inc. (Livingston, New Jersey) in March 2006 and of Polly PocketTM magnetic play sets by Mattel, Inc. (El Segundo, California) in November (4,5). However, other

^{*}Commonly neodymium iron boron or samarium cobalt magnets.

FIGURE 1. Abdominal radiograph of a boy aged 3 years, noting three attached magnets that resulted in volvulus (i.e., twisting of the bowel) and multiple bowel perforations



Photo/Consumer Product Safety Commission

toys also include magnets. CPSC is working with the ASTM International[†] toy safety standard (F 963) subcommittee to address hazards associated with toys containing magnets.

Case 1

On November 22, 2005, a boy aged 20 months, who had been in excellent health, awoke several times during the night complaining of stomach pain. During the next 2 days, he ate little, slept more than usual, and had several episodes of vomiting. His parents thought he had symptoms similar to his father's illness the preceding week. On November 24, during the boy's morning and afternoon baths, his father noted red blotches and a bluish tinge to the boy's feet and hands. Concerned about dehydration, his parents offered cool water, which the boy drank readily. He immediately became lethargic, his abdomen became visibly distended, and he exhibited intermittent loss of consciousness. The boy was taken to an emergency department, where he went into cardiopulmonary arrest within minutes of arrival. Resuscitation efforts failed, and the boy died before a definitive diagnosis was made.

A radiograph taken during resuscitation revealed a large object, measuring 30 mm by 6 mm. Because of its size, the object was thought to be outside the patient. However, at autopsy, nine cylindrical magnets, 6 mm in diameter, were found stacked together in his abdomen. The magnets had magnetically joined across two loops of intestine, causing a volvulus (i.e., twisting of the bowel) that compromised the blood supply to the bowel and led to necrosis, perforation, and sepsis. The magnets had become dislodged from an older sibling's toy building set, which included multiple plastic shapes with

magnets embedded in the corners and edges. Although the victim had not been permitted to play with this building set, he might have found dislodged magnets in the carpeting of the family playroom.

Case 2

On September 7, 2005, a boy aged 2 years, 6 months, who had been in excellent health, doubled over in pain, began vomiting, and then had diarrhea. The boy seemed to improve through the next week as his vomiting ceased, although his diarrhea and stomach ache continued. On September 15, after drinking a large amount of water, he began protracted vomiting. The next day, the boy's pediatrician diagnosed dehydration and a suspected bowel obstruction; the boy was sent immediately to the local hospital.

Hospital radiographs revealed a rod-shaped object in the boy's abdomen. His mother recognized the object as three magnetic, rod-shaped pieces from his older sibling's building set, which were attached end to end. The boy was transferred to a health-care facility that had a pediatric surgeon. During laparoscopy the next day, one piece, which had perforated the cecum, fell into the peritoneal cavity. That piece was recovered by open abdominal surgery; the remaining pieces were located in the stomach and removed endoscopically. Each piece measured 25 mm by 7 mm. When shown the pieces, the boy called them "candy." He was discharged from the hospital after 1 week.

Case 3

On May 5, 2006, while using his teeth to separate magnetic pieces from a toy building set, a boy aged 5 years, 1 month, inadvertently swallowed one of the pieces. The boy's mother became concerned he might have swallowed a button battery component of the set; she called the boy's pediatrician, who advised her to take him to a local hospital. Radiographs revealed the magnetic piece in the child's stomach. Doctors advised the mother that the piece would probably pass normally but that she should monitor the child's stool for up to 5 days. Two days later, the boy told his mother that he had swallowed another toy, a small metal ball; this did not concern her.

By May 18, the mother reported that the magnet and metal ball had not passed; the child's pediatrician ordered another radiograph. Imaging-center staff members reported finding two metal objects stuck together farther along the intestines and advised that they would probably pass naturally. However, on May 24, the pediatrician ordered another radiograph, which showed that the objects had not moved. The next day, the mother informed the pediatrician that she had learned of

[†]Originally known as the American Society for Testing and Materials.


a fatality that occurred after ingestion of magnets. After consultation with specialists on May 26, an endoscopy was scheduled for May 31. On May 30, the boy began vomiting and was taken to the specialist's hospital and admitted. During endoscopy on May 31, the toy pieces could not be removed, and surgery was required. The surgeon removed two disc-shaped magnets, each 10 mm in diameter, from the boy's large intestine and a steel ball, also 10 mm in diameter, from the small intestine and resected the affected bowel. The patient was discharged on June 2.

Summary

Building sets and toys with powerful rare-earth magnets have been marketed for use by children as young as 3 years. Among the 20 identified cases of magnet ingestion injury, the patients ranged in age from 10 months to 11 years, 6 months (mean: 5 years, 6 months; median: 4 years, 9 months−5 years); 16 (80%) of the patients were aged ≥3 years (Figure 2). Boys accounted for 16 (80%) of the patients. One fatality caused by volvulus, bowel necrosis, and sepsis was identified. Diagnoses in 15 (75%) of the cases included bowel perforations; bowel obstruction and peritonitis each were cited in four cases, and volvulus was cited in three cases (Table). Of the 14 cases for which such data were available, hospital stays ranged from 3 to 19 days (mean: 8.7 days); at least five patients required intensive care.

Among the 20 patients, two children each swallowed 15 magnets; the other 18 children swallowed from one (plus a nonmagnetic metal piece) to nine magnets. In 12 cases, magnets had been dislodged from toy pieces; in three cases, entire magnetic pieces were swallowed intact. Ten children swallowed magnets from their own toys, three swallowed magnets from

FIGURE 2. Identified cases of children with gastrointestinal injuries from ingested magnets, by age — United States, 2003–2006



SOURCE: Consumer Product Safety Commission.

an older sibling's toy, and three swallowed magnets from toys at day care facilities or school. At least five of the children swallowed magnets or magnetic pieces intentionally, including two who thought they were candy and one who swallowed three magnets on a dare. Five children had potentially relevant conditions, including autism, attention-deficit/hyperactivity disorder, developmental delays, and neurologic disorder (Table).

Reported by: J Midgett, PhD, Div of Human Factors; S Inkster, PhD, Div of Health Sciences; R Rauchschwalbe, MS, M Gillice, Office of Compliance, Consumer Product Safety Commission. J Gilchrist, MD, Div of Unintentional Injury Prevention, National Center for Injury Prevention and Control, CDC.

Editorial Note: Recent improvements in manufacturing processes have made small, powerful magnets inexpensive and readily available, increasing the potential for exposure of children to magnets in toys and other products. Ingestion of multiple magnets, or ingestion of one magnet and a metal component attracted to magnets, poses a unique health hazard (6,7). Although these magnets generally are small enough to pass through the digestive tract, they can attach to each other across intestinal walls, causing obstructions and perforations. Initial signs and symptoms of injury are nonspecific, leading to delayed diagnosis and greater injury. Even when caregivers know a child has swallowed magnets, they might assume that such small pieces will pass normally. On radiologic examination, a health-care provider cannot ascertain whether objects swallowed are magnetic and whether they are in separate sections of the gastrointestinal tract with tissue between them. To aid with diagnosis, a compass might be passed close to the abdomen to determine whether an unidentified object in the bowel is magnetic. Once magnetically attached across bowel walls, magnets are unlikely to disengage spontaneously.

Building sets and other toys containing magnets pose a substantial hazard to children who commonly mouth objects. Manufacturers of any consumer product containing magnets should take precautions to keep the magnets in their intended positions within plastic pieces and should consider making larger plastic pieces to minimize the likelihood of ingestion. Similar injuries have resulted from ingestion of magnetic beads, jewelry, and homeopathic aids (8,9).

Caregivers should keep products with magnets out of environments where children aged <6 years are playing and be aware of the unique risks if ingested. Magnets should never be used to emulate tongue or lip piercing. If caregivers suspect a child has ingested a magnet, they should seek health care

[§] The patient must be in an area clear of magnetic fields (e.g., computer monitors or electronic equipment).

TABLE. Characteristics of identified cases of children with gastrointestinal injuries from ingested magnets, by age — United States, 2003–2006

Age	Sex	No. of magnets and other pieces ingested	Diagnosis	Items ingested and circumstances	Potentially relevant conditions
10 mos	Boy	15 magnets	Foreign bodies embedded in stomach lining	Dislodged magnets from older sibling's toy	
20 mos	Boy	Nine magnets	Volvulus, necrosis, and sepsis resulting in death	Dislodged magnets from older sibling's toy	
2 yrs, 4 mos	Boy	Three magnets	Bowel perforations	Unknown	
2 yrs, 6 mos	Boy	Three rod-shaped pieces (with six magnets)	Small bowel obstruction; bowel perforations and ulcerations	Intact pieces of older sibling's toy; thought they were candy	
3 yrs, 5 mos	Boy	Three magnets	Ischemic small bowel from volvulus; 20 cm resected	Dislodged magnets from own toy	
3 yrs, 6 mos	Boy	Three magnets	Volvulus; eight bowel perforations	Dislodged magnets from own toy; thought they were candy	
4 yrs	Boy	Two magnets	Perforations in large and small bowel	Pieces from own toy	Autism
4 yrs, 2 mos	Boy	Three magnets	Peritonitis from cecal perforations	Dislodged magnets from own toy	
4 yrs, 6 mos	Boy	Three magnets	Foreign body causing small bowel obstruction; ileal fistula; peritonitis	Dislodged magnets from toy at day care facility	
4 yrs, 9 mos	Boy	Two magnets	lleal obstruction; multiple small bowel perforations	Dislodged magnets from own toy	
5 yrs, 1 mo	Boy	Two magnets, plus one metal ball	Perforations in small and large bowel	While separating pieces with teeth, inadvertently ingested dislodged magnets from own toy; later swallowed a metal ball	
5 yrs, 8 mos	Boy	Four magnets	Intestinal obstruction; multiple bowel perforations	Intentionally swallowed four dislodged magnets from toy at day care facility	Possible attention- deficit/hyperactivity disorder (ADHD)
6 yrs	Boy	Five magnets	Three bowel perforations	Unknown	
6 yrs, 11 mos	Girl	One magnet, plus one metal disc	Superficial ulcerations where sections were affixed	Attached own toy as mock tongue piercing; inadvertently swallowed	
7 yrs	Girl	Two magnets	Bowel perforations; peritonitis	Unknown	
8 yrs	Girl	Two magnets	Bowel perforations	Unknown	
8 yrs, 2 mos	Boy	15 magnets	Bowel perforations; necrosis	Dislodged magnets from own toy at grandparents' home	Developmental delays
9 yrs, 4 mos	Girl	Three magnets, plus one metal ball	Four bowel perforations; peritonitis	Dislodged magnets from own toy	Neurologic disorder and developmental delays
11 yrs	Boy	One rod-shaped piece (with two magnets), plus one metal ball	Four bowel perforations	Intentionally swallowed intact piece of own toy and steel ball as experiment	
11 yrs, 6 mos	Boy	Three magnets	Pneumoperitoneum secondary to bowel perforations; 13 cm of colon resected	Intentionally swallowed classmate's magnets on a dare at school	ADHD

SOURCE: Consumer Product Safety Commission.

promptly. Caregivers also should be aware that children might be reticent to admit ingestion or unable to describe what they have ingested. Delays in diagnosis and treatment can lead to serious or fatal outcomes.

Additional information regarding toy hazard recalls is available at http://www.cpsc.gov/cpscpub/prerel/category/toy.html. Information on product recalls from CPSC and five other federal agencies is available at http://www.recalls.gov.

References

- CDC. Nonfatal choking-related episodes among children—United States, 2001. MMWR 2002;51:945–8.
- Kay M, Wyllie R. Pediatric foreign bodies and their management. Curr Gastroenterol Rep 2005;7:212–8.
- Uyemura MC. Foreign body ingestion in children. Am Fam Physician 2005;72:287–91.
- Consumer Product Safety Commission. Child's death prompts replacement program of magnetic building sets. Release 06-127. Washington, DC: Consumer Product Safety Commission; March 31, 2006. Available at http://www.cpsc.gov/cpscpub/prerel/prhtml06/06127.html.
- Consumer Product Safety Commission. Serious injuries prompt recall
 of Mattel's Polly Pocket magnetic play sets. Release 07-039. Washington, DC: Consumer Product Safety Commission; November 21, 2006.
 Available at http://www.cpsc.gov/cpscpub/prerel/prhtml07/07039.html.
- 6. McCormick S, Brennan P, Yassa J, Shawis R. Children and mini-magnets: an almost fatal attraction. Emerg Med J 2002;19:71–3.
- 7. Oestreich AE. Danger of multiple magnets beyond the stomach in children. J Natl Med Assoc 2006;98:277–9.
- 8. Haraguchi M, Matsuo S, Tokail H, et al. Surgical intervention for the ingestion of multiple magnets by children. J Clin Gastroenterol 2004;38:915–6.
- 9. Tay ET, Weinberg G, Levin TL. Ingested magnets: the force within. Pediatr Emerg Care 2004;20:466–7.

Environmental Barriers to Health Care Among Persons with Disabilities — Los Angeles County, California, 2002–2003

In 2002, an estimated 51.2 million persons in the United States (approximately 18.1% of the population) had a disability (1). Recent data suggest that substantial disparities in health behaviors and overall health status exist between persons with and without disabilities (2). Nonetheless, when they have access to adequate health care, persons with disabilities can lead healthy lives (3,4). The World Health Organization's International Classification of Functioning, Disability, and Health stresses the importance of environment (e.g., physical environment, attitudes of others, or policies) as either a barrier or facilitator in the daily activities of persons with disabilities (5). In addition, increasing access to health and wellness treatment programs for persons with disabilities and reducing the proportion of persons with disabilities who report environmental barriers to participation in daily activities are goals of

Healthy People 2010 (objectives 6-12). However, few population-based studies have explored how environment affects the lives of those with disabilities. To determine the prevalence of disability among persons in Los Angeles County, California, and assess the effects of environmental barriers on these persons, residents were surveyed during 2002–2003. The results of that survey suggested that persons with physical or sensory disabilities experienced several environmental barriers and that the prevalence of barriers varied by demographic characteristics, household income, and severity of disability. To improve quality of life among persons with disabilities, public and private health agencies should implement measures to remove environmental barriers to health care and other services.

The Los Angeles County Health Survey is a biennial, random-digit-dialed telephone survey of the adult, noninstitutionalized population of Los Angeles County (6). Adults aged >18 years were surveyed during October 2002– February 2003, and interviews were conducted in several languages (i.e., English, Spanish, and four Asian languages). Of the 14,154 eligible adults contacted, 8,167 (57.7%) completed the interview. Persons were classified as having a disability if they answered "yes" to at least one of the following questions regarding any long-term impairment that lasted or was expected to last for at least 3 months: 1) "Are you limited in any way in any activities because of a physical, mental, or emotional problem?" 2) "Do you now have any health problems that require you to use special equipment such as a cane, a wheelchair, a special bed, or a special telephone?" and 3) "Do you consider yourself a person with a disability?" Persons who were classified as having a disability were then asked questions to determine whether their disability was physical, sensory, mental, or learning; respondents could report more than one type of disability. Respondents also were asked whether their disability was slight, moderate, or severe; definitions for severity level were not provided and were based on respondent perception.

This analysis was restricted to those who reported physical or sensory disabilities. Respondents were asked, "Which of the following best describes your disability?" Those who indicated that they experienced one or both of the following limitations were classified as having a physical disability: 1) a lack of mobility (e.g., walking or going upstairs) or 2) a limitation in body movement, such as standing, sitting, crouching, or bending or difficulty gripping, holding, or manipulating small objects or carrying light loads. Respondents who indicated that they experienced one or both of the following limitations were classified as having a sensory disability: 1) difficulty hearing (except for loud noises) or 2) difficulty seeing, including difficulty reading newspaper print.

The survey also assessed the prevalence of the following five environmental barriers related to disability: 1) experiencing restricted social activity, 2) not knowing where to obtain disability resource information, 3) needing home modifications but not having them, 4) having difficulty accessing a healthcare provider's office because of its physical layout or location, and 5) being treated unfairly at a health-care provider's office. To determine the prevalence of these barriers, participants were asked the following questions: 1) "Do you agree with the statement 'I don't participate in as many social activities as I would like because of my disability?" 2) "Do you know where to get information about community resources for people with disabilities?" 3) "Could you benefit from, but do not have, special modifications or adaptive equipment in your home?" 4) "Does the location or layout of your health-care provider's office keep you from getting needed care?" and 5) "Have you been treated unfairly by a health-care provider or the provider's staff because of a disability?" Data were weighted to reflect the sex, age, and racial/ethnic distribution of the county population on the basis of 2002 projections from the U.S. Census Bureau. Results were stratified by sex, age, race/ethnicity, household income, self-reported general health status, type of disability, and severity of disability. Results were age adjusted to the 2000 U.S. population aged \geq 18 years.

Overall, 1,333 (17.3%) of 8,115 respondents in Los Angeles County reported having a physical or sensory disability, a percentage consistent with national estimates (7–9). The prevalence of disability was highest among those aged ≥60 years, non-Hispanic blacks, and men, with 517 (32.6%), 221 (28.7%), and 662 (18.3%) reporting disabilities, respectively. Among the 1,333 reporting physical or sensory disabilities, 1,220 (90.4%) reported a physical disability, and 700 (48.3%) reported a sensory disability; 587 (44%) reported both a physical and sensory disability. A total of 495 (35.5%) respondents reported having moderate disabilities, 481 (35.1%) reported severe disabilities, and 324 (29.3%) reported slight disabilities (Table 1).

Among persons with a physical or sensory disability, 1,123 (84.7%) reported environmental barriers related to their disability. A total of 820 (62.1%) reported that their disability restricted social activity; 256 (70.3%) persons with lower incomes, 144 (66.0%) blacks, and 257 (64.5%) Hispanics reported this barrier. Overall, 774 (60.4%) respondents did not know where to obtain disability resource information. Those who were aged 18–39 years, were not white (i.e., black, Hispanic, or Asian), or had lower incomes were most likely to report difficulty acquiring disability resource information (Table 2).

TABLE 1. Number and percentage of residents* of Los Angeles County with a physical or sensory disability, by selected characteristics — Los Angeles County Health Survey, California, 2002–2003

2411011114, 2002 2000			
Characteristic	No.	(%†)	(95% CI§)
Total no. of persons with a disability	1,333	(17.3)	(16.5–18.2)
Type of disability¶			
Physical	1,220	(90.4)	(88.5-92.3)
Sensory	700	(48.3)	(45.4–51.2)
Severity of disability			
Slight	324	(29.3)	(26.5-32.2)
Moderate	495	(35.5)	(32.7 - 38.4)
Severe	481	(35.1)	(32.3–38.0)
Sex			
Male	662	(18.3)	(17.0–19.5)
Female	670	(16.5)	(15.4–17.6)
Age group (yrs)**			
18–39	289	(7.6)	(6.8-8.5)
40–59	526	(19.3)	(17.8–20.8)
≥60	517	(32.6)	(30.3-34.9)
Race/Ethnicity			
White, non-Hispanic	583	(18.5)	(17.1–19.8)
Hispanic	413	(16.1)	(14.7-17.6)
Black, non-Hispanic	221	(28.7)	(25.6–31.8)
Asian, non-Hispanic	110	(10)	(8.3–11.7)
Household income			
<100% FPL ^{††}	376	(25.9)	(23.8–28.1)
≥100% FPL	957	(15.4)	(14.5–16.2)
General health status			
Good/Excellent	651	(11.3)	(10.5–12.1)
Fair/Poor	680	(35.2)	(33.1–37.4)

- * N = 8,115 respondents. Persons with missing information were excluded. Percentages might not equal 100 because of rounding.
- [†] Age-adjusted to the 2000 U.S. standard population aged ≥18 years.
- § Confidence interval.
- Respondents could report more than one type of disability.
- ** Data not age adjusted.
- ^{††} Based on 2002 federal poverty level (FPL) thresholds at time of interview, which for a family of four (two adults and two dependents) correspond to annual incomes of \$18,859 (100% FPL), \$37,718 (200% FPL), and \$56,557 (300% FPL).

A total of 311 (24.6%) persons with physical or sensory disabilities reported needing home modifications but not having them. Among those who needed home modifications, 114 (32.8%) had incomes below the 100% federal poverty level (FPL), which is an annual salary of \$18,859 for a family of four (with two adults and two dependents). Of those with disabilities, 122 (32.1%) Hispanics and 83 (36.7%) blacks did not have needed modifications, compared with 74 (13.8%) whites (Table 2).

Twenty-two percent of persons with disabilities reported difficulty accessing a health-care provider's office because of the physical layout or location of the property. Prevalence was highest for blacks (276 [33.0%]) and those with lower incomes (104 [31.1%]). Difficulty accessing a provider's office increased with severity of disability. Approximately 167 (12.9%) reported unfair treatment at a provider's office

TABLE 2. Number and percentage of residents* of Los Angeles County with a physical or sensory disability reporting environmental barriers, by selected characteristics — Los Angeles County Health Survey, California, 2002–2003

			stricted activity	to	obtain	ow where disability nformation	i	not hav	but did e home cations	acce	essing	fficulty health-care ''s office	hea	Ith-care	infairly at provider's of disability
Characteristic	No.	(%†)	(95% CI§)	No.	(%)	(95% CI)	No.	(%)	(95% CI)	No.	(%)	(95% CI)	No.	(%)	(95% CI)
Overall	820	(62.1)	(59.1–65.1)	774	(60.4)	(57.4-63.3)	311	(24.6)	(22.0-27.3)	276	(22.0)	(19.4–24.6)	167	(12.9)	(10.9–15.0)
Sex															
Male	396	(60.1)	(56.0-64.2)	369	(59.4)	(55.4-63.4)	155	(23.9)	(20.1-27.7)	144	(23.0)	(19.4-26.6)	77	(11.9)	(9.2-14.6)
Female	424	(64.2)	(60.0-68.6)	403	(60.6)	(56.3-65.0)	155	(24.9)	(21.1–28.6)	132	(20.8)	(17.2-24.5)	89	(13.9)	(10.8-17.0)
Age group (yrs) ¹															
18–39	170	(59.2)	(53.5-64.8)	181	(62.9)	(57.1 - 68.2)	78	(24.9)	(20.2-30.3)	68	(24.1)	(19.5-29.4)	39	(13.6)	(10.1 - 18.0)
40-59	326	(63.7)	(59.4-67.7)	314	(61.0)	(56.7-65.1)	123	(24.6)	(21.0-28.6)	100	(19.7)	(16.5-23.4)	65	(12.5)	(9.9-15.6)
<u>≥</u> 60	324	(64.9)	(60.6-69.0)	279	(54.8)	(50.5-59.1)	118	(24.2)	(20.6-28.2)	108	(21.8)	(18.4-25.7)	63	(12.5)	(9.9-15.6)
Race/Ethnicity															
White, non-Hispanic	353	(60.6)	(55.5-65.7)	301	(47.7)	(42.4 - 52.8)	74	(13.8)	(10.1-17.4)	83	(14.4)	(10.8-18.1)	69	(14.7)	(10.8-18.7)
Hispanic	257	(64.5)	(59.6–69.4)	287	(70.8)	(66.2-75.3)	122	(32.1)	(27.2–36.9)	98	(26.0)	(21.5–30.6)	45	(10.0)	(6.6–13.4)
Black, non-Hispanic	144	(66.0)	(59.1–72.9)	140	(65.7)	(60.0-72.5)	83	(36.7)	(29.8–43.6)	72	(33.0)	(26.2-40.0)	43	(18.4)	(12.9-23.9)
Asian, non-Hispanic	62	(53.3)	(42.5-64.2)	71	(62.4)	(51.8-73.0)	31	(24.8)	(16.1-33.4)	21	(19.5)	(10.9-28.1)	9	(7.8)	(2.2-13.3)
Household Income															
<100% FPL**	256	(70.3)	(65.3-75.3)	255	(70.8)	(65.9 - 75.7)	114	(32.8)	(27.5-37.9)	104	(31.1)	(26.1 - 36.6)	60	(16.0)	(12.0-20.0)
≥100% FPL	564	(58.2)	(54.5–61.8)	518	(55.3)	(51.7–59.0)	197	(20.9)	(17.9–23.9)	171	(17.4)	(14.6–20.2)	107	(11.6)	(9.2–14.0)
Severity of disability															
Slight	132	(41.9)	(36.3-47.4)	182	(56.0)	(50.5-61.5)	47	(15.0)	(11.0-19.1)	44	(13.8)	(9.9-17.6)	23	(6.9)	(4.1 - 9.6)
Moderate	312	(66.0)	(60.9–71.0)	286	(61.4)	(56.1–66.6)	102	(21.8)	(17.3–26.3)	89	(20.6)	(16.1-25.2)	57	(13.8)	(9.8–17.7)
Severe	357	(75.8)	(71.1–80.5)	288	(63.3)	(58.2–68.4)	152	(34.0)	(28.7–39.2)	132	(30.9)	(25.7–36.1)	81	(18.0)	(13.7–22.2)

 $^{^{\}star}$ N = 1,333 respondents with a disability. Persons with missing information were excluded.

because of a disability; prevalence of reported unfair treatment increased with severity of disability and lower income (Table 2).

Reported by: E Bancroft, MD, A Lightstone, MPH, P Simon, MD, Los Angeles County Dept of Health Svcs. J Crews, DPA, National Center on Birth Defects and Developmental Disabilities; E Baraban, PhD, EIS Officer, CDC.

Editorial Note: These findings highlight the need for environmental improvements to reduce social isolation and facilitate activities of daily living among persons with disabilities. The results also underscore the need for public health practitioners, health-care providers, and community organizations to take a proactive role in removing environmental barriers. For example, social isolation might be decreased by ensuring that social venues such as movie theaters, restaurants, and stores are following the Americans With Disabilities Act building accessibility standards and by providing reliable, community-based transportation to such venues.

To increase access to information, public health practitioners might compile lists of community-related disability resource information and distribute them to local health-care centers and physicians' offices. Accessibility to offices of health-care providers could be improved by lowering service counters and examination tables and ensuring that scales are wheel-chair accessible. Treatment by health-care providers could be improved by educating providers about ways to make appointments run more smoothly. For example, providers should sit

down when addressing a person in a wheelchair, speak directly to the patient (rather than to a spouse or friend) when providing information, clearly enunciate when addressing a person with a hearing loss, and schedule extra appointment time for persons who might take longer to dress or get up and down from the examination table (because of a physical disability) or take longer to provide information (because of a sensory disability). In addition, researchers should consider including disability and environmental questions in other population-based surveys to assess the unmet needs of persons with disabilities. Taking these steps will help address certain CDC Health Protection Goals (priority areas for research, investment, and evaluation), one of which is achieving the best possible quality of life by increasing the number of adults who are able to participate fully in life activities (10).

The results of this study are subject to at least three limitations. First, the true prevalence of persons with disabilities might be underestimated because 42% of those contacted did not participate. In addition, the survey did not include residents of assisted-living facilities or nursing homes. Second, after stratifying the data, certain results might be statistically unreliable because of small sample sizes. Finally, because of the diversity and large geographic area and population size of Los Angeles County (i.e., approximately 4,000 square miles and 10.2 million residents), the results might not be generalizable to smaller or more homogenous populations.

[†] Age-adjusted to the 2000 U.S. standard population aged ≥18 years.

[§] Confidence interval.

[¶] Data not age adjusted.

^{**} Based on 2002 rederal poverty level (FPL) thresholds at time of interview, which for a family of four (two adults and two dependents) correspond to annual incomes of \$18,859 (100% FPL), \$37,718 (200% FPL), and \$56,557 (300% FPL).

The results indicate that 84.7% of persons with disabilities reported environmental barriers, including social isolation, trouble obtaining resource information, difficulty accessing needed health care because of the office layout or location of a health-care provider, and unfair treatment by a health-care provider. These results indicate the need for health-care providers and public health officials to address such concerns, in the community and the home, to improve overall health and quality of life and reduce the disparities that exist between persons with and without disabilities.

References

- 1. Steinmetz E. Americans with disabilities: 2002. Current population reports. Washington, DC: US Census Bureau; 2006. Available at http://www.census.gov/prod/2006pubs/p70-107.pdf.
- CDC. 2006 disability and health state chartbook: profiles of health for adults with disabilities. Atlanta, GA: US Department of Health and Human Services, CDC; 2006.
- 3. US Department of Health and Human Services. The Surgeon General's call toaction to improve the health and wellness of persons with disabilities. Washington, DC: US Department of Health and Human Services, Office of the Surgeon General; 2005.
- 4. US Department of Health and Human Services. Healthy people 2010 (conference ed, in 2 vols). Washington, DC: US Department of Health and Human Services; 2000. Available at http://www.health.gov/healthypeople.
- World Health Organization. International classification of functioning, disability, and health (ICF). Geneva, Switzerland: World Health Organization; 2001.
- Simon PA, Wold CM, Cousineau MR, Fielding JE. Meeting the data needs of a local health department: the Los Angeles County Health Survey. Am J Public Health 2001;91:1950–2.
- 7. McNeil JM. Americans with disabilities: 1994–95. Washington, DC: US Department of Commerce, Economics, and Statistics Administration, Bureau of the Census; 1997. (Current populations report; series P70, no. 61).
- 8. CDC. State-specific prevalence of disability among adults—11 states and the District of Columbia, 1998. MMWR 2000;49:711–4.
- CDC. Prevalence of disabilities and associated health conditions among adults—United States, 1999. MMWR 2001;50:120–5.
- CDC. Health protection goals. Atlanta, GA: US Department of Health and Human Services, CDC; 2006. Available at http://www.cdc.gov/ about/goals/health_protection_goals.pdf.

Erratum: Vol. 55, No. 17

In the report, "Worker Illness Related to Ground Application of Pesticide—Kern County, California, 2005," an error occurred in the first sentence on page 488. The sentence should read, "During 1998–2003 in California, 12% (297 of 2,470) of occupational pesticide illness reports were attributed to pesticide drift (SENSOR-Pesticides Program, California, unpublished data, 2005)."

Erratum: Vol. 55, No. 45

In the report, "Fatalities and Injuries from Falls Among Older Adults—United States, 1993–2003 and 2001–2005," an error occurred in the References on page 1224. Reference 9 should read, "Miniño AM, Heron MP, Smith BL. Deaths: preliminary data for 2004. Natl Vital Stat Rep 2006;54(19)."

Errata: Vol. 55, No. RR-15

In the MMWR Recommendations and Reports, "General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)," in Table 9, on page 21, the vaccine storage temperatures in Celsius were incorrect for measles, mumps, rubella, and varicella vaccine; live-attenuated influenza vaccine; varicella vaccine; and herpes zoster vaccine. Following is the corrected table:

TABLE 9. Vaccine storage temperature recommendations

Vaccines	Vaccine storage temperature	Diluent storage temperature	Instructions
Diphtheria-tetanus, or pertussis-containing vaccines	35°F–46°F (2°C–8°C) Do not freeze	No diluent*	Aluminum adjuvant – irreversible loss of potency with exposure to freezing temperature
Haemophilus influenzae type b conjugate vaccines (Hib)	35°F–46°F (2°C–8°C) Do not freeze	35°F–46°F (2°C–8°C) Do not freeze	Several vaccine types with different thermostability profiles [†]
Hepatitis A and hepatitis B vaccines	35°F–46°F (2°C–8°C) Do not freeze	No diluent	Aluminum adjuvant – irreversible loss of potency with exposure to freezing temperature
Inactivated polio vaccine	35°F–46°F (2°C–8°C) Do not freeze	No diluent	Data on thermostability properties of this vaccine are lacking
Meningococcal conjugate vaccine	35°F–46°F (2°C–8°C) Do not freeze	No diluent	Data on thermostability properties of this vaccine are lacking. Do not expose to light
Meningococcal polysaccharide vaccine	35°F–46°F (2°C–8°C) Do not freeze	Data are lacking on ideal pre-reconstitution storage requirements. After reconstitution, vaccine should be stored at 35°F–46°F (2°C–8°C).Do not freeze	Lyophilized (freeze-dried) vaccine. Data on the effect of freezing temperatures on potency are lacking
Pneumococcal conjugate vaccine	35°F–46°F (2°C–8°C) Do not freeze	No diluent	Aluminum adjuvant – irreversible loss of potency with exposure to freezing temperatures
Pneumococcal polysaccharide vaccine	35°F–46°F (2°C–8°C) Do not freeze	No diluent	Data on thermostability properties of this vaccine are lacking
Measles, mumps, and rubella vaccine in the lyophilized (freeze-dried) state§	35°F-46°F (2°C-8°C) Lyophilized (freeze-dried) vaccine can be stored at freezer temperature	35°F-77°F (2°C-25°C) Can be refrigerated or stored at room temperature	Protect from light or temperatures above the recommended range
Measles, mumps, rubella, and varicella vaccine	≤5°F (≤-15°C)	35°F-77°F (2°C-25°C) Can be refrigerated or stored at room temperature	Protect from light
Trivalent inactivated influenza vaccine	35°F–46°F (2°C–8°C) Do not freeze	No diluent	Data on the thermostability properties of this vaccine are lacking
Live-attenuated influenza vaccine	≤5°F (≤-15°C)	No diluent	Do not expose to temperatures above the recommended range
Varicella vaccine	≤5°F (≤-15°C)	35°F–77°F (2°C–25°C) Can be refrigerated or stored at room temperature	Do not expose to light or temperatures above the recommended range
Herpes zoster vaccine	≤5°F (<u><</u> -15°C)	35°F–77°F (2°C–25°C) Can be refrigerated or stored at room temperature	Protect from light
Rotavirus	35°F–46°F (2°C–8°C) Do not freeze	No diluent	Protect from light
Human papillomavirus vaccine	35°F–46°F (2°C–8°C) Do not freeze	No diluent	Protect from light

^{*} DTaP-Tripedia® is sometimes used as a diluent for ActHib®.

[†] ActHIB® (Aventis Pasteur, Lyon, France) in the lyophilized state is not expected to be affected detrimentally by freezing temperatures, although no data are available


[§]MMR in the lyophilized state is not affected detrimentally by freezing temperatures.

Adapted from Atkinson WL, Pickering LK, Watson JC, Peter G. General Immunization Practices. In: Plotkin SA, Orenstein WA, eds. Vaccine. 4th ed. Philadelphia: Elsevier; 2004. p. 1357-86 and CDC. Guidelines for maintaining and managing the vaccine cold chain. MMWR 2003;52:1023–5.

QuickStats

FROM THE NATIONAL CENTER FOR HEALTH STATISTICS

Percentage of Men Aged ≥40 Years* with Prostate-Specific Antigen (PSA) Levels of ≥2.5 and ≥4.0 ng/mL, by Race/Ethnicity — National Health and Nutrition Examination Survey, United States, 2001–2004



^{*} Men were excluded from PSA testing if they reported prostate cancer, current prostate infection, prostate biopsy, or cystoscopy within the preceding 30 days or digital rectal examination within the preceding 7 days.

Although screening for prostate cancer using the PSA test is common, clinicians are divided over whether the screening test is effective and whether a lower PSA threshold should be used to refer patients for prostate biopsy to rule out cancer. A PSA level of \geq 4.0 ng/mL is the common threshold; however, certain researchers have recommended lowering the level to \geq 2.5 ng/mL. During 2001–2004, approximately 6.2% (3.6 million) of men aged \geq 40 years in the United States had a PSA level of \geq 4.0 ng/mL, and approximately 13.1% had a PSA of >2.5 ng/mL. Differences among racial/ethnic groups tested were not statistically significant.

SOURCES: Lacher DA, Thompson TD, Hughes JP, Saraiya M. Total, free, and percent free prostate-specific antigen levels among U.S. men, 2001–04. Adv Data 2006;379. Available at http://www.cdc.gov/nchs/data/ad/ad379.pdf.

Catalona WJ, Loeb S, Han M. Viewpoint: expanding prostate cancer screening. Ann Intern Med 2006;144:441–3.

MMWR Continuing Education Exams Available for Credit

Title	MMWR Issue	Expiration Date
General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)	Vol. 55, No. RR-15	December 1, 2009
Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Woment in Health-Care Settings	Vol. 55, No. RR-14	September 22, 2009
Prevention and Control of Tuberculosis in Correctional and Detention Facilities: Recommendations from CDC Endorsed by the Advisory Council for the Elimination of Tuberculosis, the National Commission on Corrections Health Care, and the American Correctional Association	Vol. 55, No. RR-9	July 7, 2009
Mold Prevention Strategies and Possible Health Effects in the Aftermath of Hurricanes and Major Floods	Vol. 55, No. RR-8	June 9, 2009
Prevention of Hepatitis A through Active or Passive Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)	Vol. 55, No. RR-7	May 19, 2009
Recommendations to Improve Preconception Health and Health Care — United States: A Report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care	Vol. 55, No. RR-6	April 21, 2009
Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever, Ehrlichioses, and Anaplasmosis — United States: A Practical Guide for Physicians and Other Health-Care and Public Health Professionals	Vol. 55, No. RR-4	March 31, 2008
Preventing Tetanus, Diphtheria, and Pertussis Among Adolescents: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP)	Vol. 55, No. RR-3	March 24, 2009
Surveillance Guidelines for Smallpox Vaccine (vaccinia) Adverse Reaction	Vol. 55, No. RR-1	February 3, 2009
Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Settings, 2005	Vol. 54, No. RR-17	December 30, 2008
A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of Infants, Children, and Adolescents	Vol. 54, No. RR-16	December 23, 2008
Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis: Recommendations from the National Tuberculosis Controllers Association and CDC	Vol. 54, No. RR-15	December 16, 2008
Good Laboratory Practices for Waived Testing Sites: Survey Findings from Testing Sites Holding a Certificate of Waiver Under the Clinical Laboratory Improvement Amendments of 1988 and Recommendations for Promoting Quality Testing	Vol. 54, No. RR-13	November 11, 2007
Guidelines for Identifying and Referring Persons with Fetal Alcohol Syndrome	Vol. 54, No. RR-11	October 28, 2007
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis	Vol. 54, No. RR-9	September 30, 2007
Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)	Vol. 54, No. RR-7	May 27, 2008
Compendium of Measures To Prevent Disease Associated with Animals in Public Settings, 2005: National Association of State Public Health Veterinarians, Inc. (NASPHV)	Vol. 54, No. RR-4	March 25, 2007
Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States: Recommendations from the U.S. Department of Health and Human Services	Vol. 54, No. RR-2	January 21, 2008
Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America	Vol. 53, No. RR-15	December 17, 2007
Treating Opportunistic Infections Among HIV-Exposed and Infected Children: Recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America	Vol. 53, No. RR-14	December 3, 2007
Newborn Screening for Cystic Fibrosis: Evaluation of Benefits and Risks and Recommendations for State Newborn Screening Programs	Vol. 53, No. RR-13	October 15, 2007
Medical Examiners, Coroners, and Biologic Terrorism: A Guidebook for Surveillance and Case Management	Vol. 53, No. RR-8	June 11, 2007
Diagnosis and Management of Foodborne Illnesses: A Primer for Physicians and Other Health Care Professionals	Vol. 53, No. RR-4	April 16, 2007
Applying Public Health Strategies to Primary Immunodeficiency Diseases: A Potential Approach to Genetic Disorders	Vol. 53, No. RR-1	January 16, 2007
Guidelines for Infection Control in Dental Health-Care Settings — 2003	Vol. 52, No. RR-17	December 19, 2006

http://www.cdc.gov/mmwr/cme/conted.html

TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week anding December 2, 2006 (48th Week)

		•	5-year	Total	cases rep	orted for	r nreviou	e voare	
Disease	Current week	Cum 2006	weekly average [†]	2005	2004	2003	2002	2001	States reporting cases during current week (No.
Anthrax		1	0				2	23	
Botulism:			ŭ				_		
foodborne	_	13	1	19	16	20	28	39	
infant	_	73	1	90	87	76	69	97	
other (wound & unspecified)	1	44	1	33	30	33	21	19	CA (1)
Brucellosis	_	102	2	122	114	104	125	136	5/1(1)
Chancroid	1	27	1	17	30	54	67	38	TX (1)
Cholera		6	0	8	5	2	2	3	17(1)
Cyclosporiasis§	_	111	1	716	171	75	156	147	
Diphtheria	_					1	1	2	
Domestic arboviral diseases§.¶:								_	
California serogroup	_	52	1	80	112	108	164	128	
eastern equine	_	7	0	21	6	14	10	9	
Powassan	_	1	_	1	1		1	Ň	
St. Louis	_	7	0	13	12	41	28	79	
western equine	_		_	_			_	_	
Ehrlichiosis§:									
human granulocytic	35	404	9	790	537	362	511	261	NY (18), MN (16), MD (1)
human monocytic	14	375	5	521	338	321	216	142	NY (9), MN (2), AR (2), CA (1)
human (other & unspecified)		170	1	122	59	44	23	6	(5), WIT (2), ATT (2), OA (1)
Haemophilus influenzae.**		170		122	33		20	U	
invasive disease (age <5 yrs):									
		9	0	9	19	32	34		
serotype b		76	3		135		144	_	
nonserotype b	4	179	3	135 217	177	117 227	153	_	OH (2) A7 (1) OB (1)
unknown serotype Hansen disease§		68	2	88	105	95	96	— 79	OH (2), AZ (1), OR (1)
	_		0						
Hantavirus pulmonary syndrome§	_	29		29	24	26	19	8	OU (1) CA (1)
Hemolytic uremic syndrome, postdiarrheal [§]	2 4	222	4 28	221	200	178	216	202	OH (1), CA (1)
Hepatitis C viral, acute		687		751	713	1,102	1,835	3,976	NE (1), TN (1), OR (1), CA (1)
HIV infection, pediatric (age <13 yrs)§.††	_	52	6	380	436	504	420	543	
Influenza-associated pediatric mortality ^{§,§§}	 8	40	0 14	45	750	N	N	N	NIV (1) DA (1) DC (1) VA (1) EL (1) TV (1)
Listeriosis	0	661	14	892	753	696	665	613	NY (1), PA (1), DC (1), VA (1), FL (1), TX (1),
Measles ¹¹	1	45	1	66	37	56	44	116	WA (1), CA (1) MN (1)
Meningococcal disease, invasive***:		40		00	01	50	77	110	14114 (1)
A, C, Y, & W-135	_	179	5	297	_	_	_		
serogroup B	1	112	4	157			_	_	WA (1)
other serogroup	i	20	0	27	_	_	_	_	FL (1)
Mumps	73	6,201	5	314	258	231	270	266	
Plague	73	16	0	8	3	1	2/0	200	PA (3), MN (67), NE (1), KS (2)
Poliomyelitis, paralytic		_	_	1	_		_	_	
Psittacosis [§]		19	0	19	12	12	18	 25	
Q fever§	_	139	1	139	70	71	61	26 26	
Rabies, human		2	0	2	70	2	3	1	
	_	9				7			
Rubella	_			11	10		18	23	
Rubella, congenital syndrome SARS-CoV ^{§,†††}		1		1	_	1	1 N	3	
	_	_	_	_	_	8	N	N	
Smallpox [§]	_		_	100	100	101	110	— 77	
Streptococcal toxic-shock syndrome [§]	_	85	1	129	132	161	118	77	
Streptococcus pneumoniae,§	4.4	1 000	10	1.057	1.100	045	E40	400	NH (1) NV (2) IN (5) CO (1) A7 (1)
invasive disease (age <5 yrs)	11	1,009	19	1,257	1,162	845	513	498	NH (1), NY (3), IN (5), CO (1), AZ (1)
Syphilis, congenital (age <1 yr)	1	249	8	361	353	413	412	441	AZ (1)
Tetanus	-116 -1	19	1	27	34	20	25	37	OA (4)
Toxic-shock syndrome (other than streptococca	al)§ 1	89	2	96	95	133	109	127	CA (1)
Trichinellosis		11	0	19	5	6	14	22	OH (4)
Tularemia§	1	81	2	154	134	129	90	129	OH (1)
Typhoid fever	2	250	5	324	322	356	321	368	CT (1), CA (1)
Vancomycin-intermediate Staphylococcus aure		3	_	2	_	N	N	N	
Vancomycin-resistant Staphylococcus aureus§	_	_	_	3	1	N	N	N	
Yellow fever	_	_	_	_	_	_	1	_	

^{-:} No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts.

Data for *H. influenzae* (all ages, all serotypes) are available in Table II.

The one measles case reported for the current week was indigenous.

Incidence data for reporting year 2006 are provisional, whereas data for 2001, 2002, 2003, 2004, and 2005 are finalized.

Calculated by summing the incidence counts for the current week, the two weeks preceding the current week, and the two weeks following the current week, for a total of 5 preceding years. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf. Not notifiable in all states.

Includes both neuroinvasive and non-neuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (proposed) (ArboNET Surveillance).

Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (proposed). Implementation of HIV reporting influences the number of cases reported. Pediatric HIV data will not be updated monthly for the remainder of this year due to upgrading of the national HIV/ AIDS surveillance data management system. Data for HIV/AIDS are available in Table IV quarterly.

Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases (proposed).

Data for meningococcal disease (all serogroups and unknown serogroups) are available in Table II.

tht Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (proposed).

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending December 2, 2006, and December 3, 2005 (48th Week)*

(48th Week)*			Chlamyd	lia [†]			Coccid	ioidomy	cosis			Cryp	tosporio	liosis	
	0		vious	0	0	0		ious	0	0	0		vious	0	0
Reporting area	Current week	Med	veeks Max	Cum 2006	Cum 2005	Current week	Med	eeks Max	Cum 2006	Cum 2005	Current week	Med	veeks Max	Cum 2006	Cum 2005
United States	11,826	19,362	35,170	880,622	882,722	153	150	1,643	7,334	4,242	52	71	594	4,842	7,274
New England Connecticut Maine [§] Massachusetts New Hampshire Rhode Island Vermont [§]	620 126 49 407 17 3 18	650 174 42 294 38 63 20	1,550 1,214 66 606 71 107 43	30,488 8,640 2,091 14,235 1,824 2,687 1,011	29,762 8,796 2,084 13,273 1,698 3,021 890	N N — — N	0 0 0 0 0	0 0 0 0 0	N N — — N	N N - - N	2 - - 1 - 1	4 0 0 1 1 0 0	36 33 5 14 5 6	274 33 40 88 49 14 50	339 78 30 145 36 13
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	1,879 — 695 530 654	2,417 363 499 698 785	3,696 496 1,727 1,567 1,104	111,286 16,110 22,491 35,631 37,054	109,590 17,725 22,031 35,669 34,165	N N N N	0 0 0 0	0 0 0 0	N N N N	N N N N	5 -4 - 1	11 0 3 2 4	444 3 441 7 17	546 11 168 106 261	3,156 57 2,692 143 264
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	1,025 — 464 389 52 120	3,144 977 390 658 636 385	12,578 1,697 478 9,888 1,424 531	143,113 47,285 18,078 31,866 28,389 17,495	150,618 46,855 18,473 26,245 40,041 19,004	 N N	1 0 0 0 0	3 0 0 3 2	43 — N 37 6 N	11 N 11 — N	16 7 1 8 	15 2 1 2 4 5	105 18 18 8 33 53	1,186 140 97 134 343 472	1,584 157 81 106 754 486
W.N. Central lowa Kansas Minnesota Missouri Nebraska [§] North Dakota South Dakota	624 — 208 — 240 112 7 57	1,163 159 150 237 446 99 32 51	1,455 225 269 347 613 176 61 116	54,509 7,495 6,664 10,459 20,945 4,990 1,541 2,415	54,421 6,824 6,840 11,324 20,676 4,676 1,543 2,538	N N N N N N N	0 0 0 0 0 0	12 0 0 12 1 0 0	1 N N - 1 N N N	4 N N 3 1 N N N	2 — 1 — 1 —	12 1 1 3 2 1 0	77 28 8 22 21 16 4 7	809 167 78 215 174 92 9 74	595 120 39 134 244 27 1 30
S. Atlantic Delaware District of Columbia Florida Georgia Maryland [§] North Carolina South Carolina [§] Virginia [§] West Virginia	3,281 89 58 789 15 348 867 448 617 50	3,723 67 53 961 693 337 593 332 430 59	4,944 92 138 1,169 2,142 487 1,772 1,452 840 227	172,105 3,301 2,690 44,953 30,423 16,626 31,085 18,070 22,062 2,895	161,850 3,128 3,475 39,663 28,953 17,140 29,093 17,230 20,642 2,526	N	0 0 0 0 0 0 0	1 0 0 0 0 0 1 0 0	3 N N N 3 N N N	2 N N 2 N N N N	24 — 1 10 13 — — —	15 0 0 6 4 0 1 1 1	68 3 2 32 14 3 11 13 6 3	1,087 15 15 514 243 19 93 123 55	711 6 15 331 141 31 84 24 65
E.S. Central Alabama [§] Kentucky Mississippi Tennessee [§]	1,147 91 162 330 564	1,420 410 163 374 513	1,947 756 613 807 609	68,413 19,122 8,038 17,670 23,583	64,112 15,371 7,843 19,468 21,430	N N - N	0 0 0 0	0 0 0 0	N N — N	N N — N	1 - - 1	3 1 1 0 0	12 10 5 3 5	177 82 35 16 44	214 25 141 2 46
W.S. Central Arkansas Louisiana Oklahoma Texas [§]	1,070 223 31 — 816	2,177 153 235 227 1,479	3,605 335 607 2,159 1,900	99,739 7,609 11,885 11,232 69,013	101,721 7,903 16,011 10,658 67,149	 N N	0 0 0 0	1 1 1 0 0	2 1 1 N N	 N N	_ _ _ _	4 0 0 1 2	44 2 9 4 35	322 20 67 38 197	221 6 81 42 92
Mountain Arizona Colorado Idaho [§] Montana [§] Nevada [§] New Mexico [§] Utah Wyoming	330 216 — 29 — 85	1,025 368 143 46 45 85 189 94 27	1,839 881 395 191 195 432 339 176 54	46,591 17,510 5,480 2,333 2,348 4,569 8,477 4,652 1,222	57,502 19,280 14,194 2,515 2,119 6,549 7,577 4,189 1,079	92 92 N N N	108 105 0 0 0 1 0	452 448 0 0 0 4 3 3	4,972 4,846 N N N 52 15 57	2,709 2,605 N N N 63 19 19	1 1 - - - -	3 0 1 0 1 0 0 0	39 3 7 5 26 1 5 3	363 24 68 35 132 9 28 19 48	135 10 49 14 20 11 17 11
Pacific Alaska California Hawaii Oregon [§] Washington	1,850 — 1,244 — 286 320	3,319 82 2,601 101 170 348	5,079 152 4,231 135 315 604	154,378 3,657 121,416 4,735 8,223 16,347	153,146 3,931 118,834 5,102 8,230 17,049	61 61 N N	43 0 43 0 0	1,179 0 1,179 0 0	2,313 — 2,313 N N N	1,516 — 1,516 N N	1 - - 1 -	1 0 0 0 1	52 1 14 1 7 38	78 4 4 70 	319 3 192 1 67 56
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U — 77 —	0 0 18 93 5	46 0 27 190 16	U U 4,133 178	U 795 3,718 196	U U N	0 0 0 0	0 0 0 0	U U N	U U N	U U N	0 0 0 0	0 0 0 0	U U N	U U N

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-one in the common state of the co Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending December 2, 2006, and December 3, 2005 (48th Week)*

			Giardiasi	s			G	onorrhe	a		Hae 	•	<i>s influen</i> es, all se	<i>zae</i> , inva rotypes	sive
	Current	Prev 52 w		Cum	Cum	Current		/ious /eeks	Cum	Cum	Current		vious veeks	Cum	Cum
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	week	Med	Max	2006	2005
United States	191	318	1,029	15,653	17,712	4,210	6,595	14,136	306,685	304,297	29	40	142	1,824	2,043
New England Connecticut	4	22 1	75 31	1,101 271	1,580 347	102 34	110 42	288 241	5,136 2,053	5,333 2,253	1 1	2	19 9	139 44	151 44
Maine† Massachusetts	4	2 9	13 18	170 357	193 696	5 52	2 47	8 87	122 2,262	130 2,326		0	4 7	19 52	11 72
New Hampshire	_	0	9	28	61	_	3	9	176	165	_	0	2	9	8
Rhode Island Vermont [†]	_	1 3	25 12	102 173	107 176	9 2	9 1	19 4	460 63	404 55	_	0 0	7 2	6 9	7 9
Mid. Atlantic New Jersey	29	64 9	254 13	3,057 339	3,212 427	557 —	655 102	1,014 160	30,093 4,580	31,577 5,270	4	7 0	30 4	350	399 84
New York (Upstate)	20	24	227	1,164	1,118	194	121	455	5,813	6,483	1	3	27	131	112
New York City Pennsylvania	2 7	15 16	29 32	812 742	838 829	140 223	175 225	378 399	9,017 10,683	9,572 10,252	3	2 3	6 8	80 139	73 130
E.N. Central	23	48 9	82 21	2,239 359	3,105 734	551 —	1,285 378	7,047 711	58,580 18,051	61,074 18,506	5	5 1	14 6	255 47	344 114
Indiana	N	0	0	N	N	165	161	248	7,991	7,466	_	1	11	73	62
Michigan Ohio	5 18	14 16	37 32	636 762	740 742	312 26	260 303	5,880 648	13,569 12,994	10,566 19,120	<u></u>	0 2	3 6	20 84	23 103
Wisconsin	_	10	40	482	889	48	133	172	5,975	5,416	_	0	4	31	42
W.N. Central lowa	9	28 5	260 15	1,633 267	2,085 264	201	372 36	444 62	17,245 1,665	17,334 1,515	4	2	15 1	142	108
Kansas Minnesota	2 5	3 1	11 238	186 486	197 894	59 —	41 62	124 105	1,870 2,693	2,374 3,236	4	0	3 9	15 76	17 41
Missouri Nebraska†	_	9 2	28 9	492 108	486 111	101 33	190 27	252 56	9,233 1,320	8,720 1,061	_	0	6 2	32 8	32 15
North Dakota South Dakota	=	0 1	7 5	17 77	18 115	2	3	7 15	117 347	109 319	_	0	3 0	9	3
S. Atlantic	30	50	95	2,443	2,550	1,456	1,613	2,334	77,158	71,588	7	10	24	491	486
Delaware District of Columbia	3	0 1	4 4	36 60	54 52	35 32	27 35	44 61	1,371 1,721	822 1,976	_ 1	0	1 2	1 8	10
Florida Georgia	20 2	19 11	44 28	1,042 530	893 691	360 11	458 345	548 1,014	21,252 15,406	18,428 13,610	1 4	3	9 6	156 94	124 103
Maryland [†]	5 N	3	11	200 N	198	147 543	125 310	189 766	6,035	6,479	<u>-</u> 1	1 0	5 9	64	70 72
North Carolina South Carolina [†]	_	1	0 7	97	N 101	178	145	704	16,223 8,155	14,016 7,997	_	1	3	52 32	33
Virginia† West Virginia	_	8 0	50 6	445 33	516 45	138 12	130 18	288 43	6,075 920	7,609 651	_	1 0	8 4	65 19	48 26
E.S. Central	20	8 5	41 29	505 287	398	451 55	576 190	869	27,698	25,792	2	2	7 5	97 22	109
Alabama [†] Kentucky	16 N	0	0	N	183 N	71	56	311 180	8,802 2,937	8,553 2,763	_	Ō	1	5	17 12
Mississippi Tennessee [†]	4	0 4	0 12	218	 215	133 192	149 191	435 238	6,967 8,992	6,522 7,954	1 1	0 1	1 4	4 66	80
W.S. Central	_	5	31	279	305	457	898	1,430	43,230	41,512	_	1	15	61	107
Arkansas Louisiana	_	0	8 5	126 34	80 59	99 90	81 142	142 354	3,949 7,451	4,141 8,886	_	0	2	7 11	7 35
Oklahoma Texas†	N	2 0	24 0	119 N	166 N	268	82 568	764 915	4,189 27,641	4,244 24,241	_	1 0	14 1	43	57 8
Mountain	24	30	66	1,552	1,450	57	222	552	10,638	12,287	5	4	8	178	200
Arizona Colorado	4 7	3 9	36 33	145 511	138 505	36 —	92 44	201 85	4,322 2,067	4,425 2,954	2	1	7 4	80 48	98 40
Idaho† Montana†	_	3 2	12 11	173 103	145 71	_ 1	2	15 20	139 180	108 138	_	0	1 0	6	5 —
Nevada† New Mexico†	_	1 1	8 6	85 66	108 86	_	25 32	194 65	1,475 1,540	2,529 1,405	_	0	1 4	1 24	14 25
Utah Wyoming	13	7	25 4	433 36	370 27	20	18	25 6	805 110	653 75	_	0	4	16	9
Pacific	 52	59	202	2,844	3,027	378	798	967	36,907	37,800	1	2	15	111	139
Alaska California	44	1 43	17 105	96 2,022	108 2,154	258	11 660	24 834	501 30,431	537 31,471	_	0	2	9 27	27 56
Hawaii	1 4	1 8	3 14	45 360	60 393	1 34	18 27	29 49	807 1,242	952 1,440	_ 1	0	1 6	19 54	9
Oregon [†] Washington	3	7	90	321	312	85	76	142	3,926	3,400		0	4	2	47 —
American Samoa C.N.M.I.	U U	0	0	U U	U U	U	0	2	U	U U	U	0	0	U U	U
Guam	- 1	0	Ō	_	11	_	4	15	_	85	_	0	1	_	14
Puerto Rico U.S. Virgin Islands		1 0	12 0	78 —	247 —	1	5 0	16 5	248 30	336 45	_	0	0	_	4

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to* Incidence data for reporting year 2006 is provisional.

† Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending December 2, 2006, and December 3, 2005 (48th Week)*

			Α	Нер	atitis (viral	, acute), by	type	- В				1 4	egionello	eie	
	-	Prev	A /ious				Previ	B ous					vious	313	
B	Current	52 w	reeks	Cum	Cum	Current	52 we		Cum	Cum	Current	52 v	veeks	Cum	Cum
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	week	Med	Max	2006	2005
United States New England	37 2	67 3	245 20	3,098 155	3,874 436	32	83 2	574 8	3,727 88	4,454 144	28	41 2	127 12	2,229 115	2,062 144
Connecticut	2	1	2	39	48	_	0	3	29	45	_	0	9	49	33
Maine [†] Massachusetts	_	0 0	2 6	6 51	6 281	_	0 0	2 5	20 14	12 49	_	0	2 4	8 27	65
New Hampshire	_	0	16	37	80	_	0	2	13	29	_	0	1	1	9
Rhode Island Vermont [†]	_	0 0	4 2	14 8	15 6	_	0 0	4 1	9 3	3 6	_	0	10 2	22 8	21 9
Mid. Atlantic	6	6	17	328	617	1	8	55	387	611	6	14	47	836	724
New Jersey New York (Upstate)	5	1 1	5 14	71 89	146 93	1	2 1	8 43	96 58	226 56		1 6	11 30	96 307	117 197
New York City Pennsylvania	_ 1	2 1	10 5	107 61	282 96	_	2	5 9	82 151	124 205	<u> </u>	2 4	15 18	128 305	113 297
E.N. Central	2	6	13	285	348	3	8	24	372	533	10	8	26	447	419
Illinois Indiana	_	1	4	61 29	120 19	_	1	7 17	60 53	150 40	_	0	4	21 34	57 31
Michigan	_	2	8	107	114	_	3	6	131	176	1	3	11	134	110
Ohio Wisconsin	2	1 1	4 4	51 37	49 46	3	2	10 2	120 8	123 44	9	3 0	19 5	222 36	187 34
W.N. Central	_	2	30	121	85	_	3	22	150	255	_	1	15	74	93
Iowa Kansas	_	0	2 5	11 26	19 16	_	0	3 2	16 10	27 27	_	0	3 2	10 6	8
Minnesota	_	0	29	16	3	_	0	13	23	29	_	Ō	11	24	26
Missouri Nebraska [†]	_	1 0	3 2	43 17	30 16	_	1 0	6 3	78 20	141 24	_	0 0	3 2	20 9	29 4
North Dakota South Dakota	_	0	2	 8	_ 1	_	0 0	0 1	3	7	_	0 0	1 1	 5	2 21
S. Atlantic	2	10	29	517	684	15	23	66	1,071	1,284	7	8	19	416	390
Delaware District of Columbia	_	0	2 2	12 8	6 4	_ 2	1 0	4 2	46 9	30 11		0	2 5	12 32	16 12
Florida	2	4	13	200	273	7	8	19	385	448	2	3	9	148	107
Georgia Maryland [†]	_	1 1	5 6	58 61	121 71	3 1	3 3	8 10	157 139	191 146	3	0 1	3 7	23 87	37 106
North Carolina South Carolina [†]	_	0	20	94 23	82 42	1 1	0	23 7	148 75	150 143	_	0	5 1	34	31 15
Virginia [†]	_	1	11	55	81		1	18	62	125	_	1	7	61	45
West Virginia	_	0	3	6	4	_	0	18	50	40	_	0	3	15	21
E.S. Central Alabama [†]	_	2	8 3	118 18	232 43	2	6 2	18 12	335 112	345 87	_	1 0	9 2	95 10	83 13
Kentucky Mississippi	_	0	5 1	31 9	24 19	_ 1	1 1	5 3	66 34	66 49	_	0	5 2	39 3	30
Tennessee [†]	_	1	5	60	146	i	2	7	123	143	_	1	7	43	37
W.S. Central Arkansas	1	7 0	77 9	324 38	446 19	_	13 1	315 3	667 50	588 67	_	0	32 3	49 3	44 6
Louisiana	_	0	4	20	62	_	0	5	33	67	_	Ō	2	4	3
Oklahoma Texas [†]	_ 1	0 5	3 73	9 257	5 360	_	0 11	17 295	70 514	39 415	_	0	6 26	7 35	7 28
Mountain	4	5	17	244	310	_	3	16	129	175	3	2	8	116	92
Arizona Colorado	2 2	2 1	16 4	146 38	171 43	_	0 1	2 5	6 34	— 53	2 1	1 0	4 2	37 22	23 19
Idaho†	_	0	2	9	21	_	0	2	13	16	_	0	3	11	4
Montana† Nevada†	_	0 0	3 2	11 11	10 21	_	0 1	7 5	30	3 47	_	0	1 2	6 8	19
New Mexico [†] Utah	_	0	3 2	13 13	24 19	_	0	2 5	19 27	18 36	_	0	1 6	5 27	13
Wyoming	_	0	1	3	1	_	0	1	_	2	_	0	0	_	4
Pacific Alaska	20	18 0	163 0	1,006	716 4	11	11 0	61 3	528 9	519 7	2	1 0	9 0	81	73 1
California	20	15	162	904	599	9	8	41	391	350		1	9	81	69
Hawaii Oregon [†]	_	0 1	3 5	12 43	24 44	_ 1	0 1	1 5	6 76	9 94	N	0	0	N	3 N
Washington	_	0	13	47	45	1	0	18	46	59	_	0	0	_	_
American Samoa C.N.M.I.	U U	0	0	U U	1 U	U U	0	0	U U	_ U	U	0	0	U U	L
Guam	_	0	Ō	_	2	_	0	Ō	_	18	_	Ō	Ō	_	_
Puerto Rico U.S. Virgin Islands	_	0	6 0	30	63	4	0	8 0	31	51 —	1	0	1	2	_

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to* Incidence data for reporting year 2006 is provisional.

† Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 2, 2006, and December 3, 2005 (48th Week)*

(48th Week)*							Malaria					
		Dro	Lyme dis	ease				Prev		1		
	Current		reeks	Cum	Cum	C	urrent	52 w		Cum	Cum	
Reporting area	week	Med	Max	2006	2005		veek	Med	Max	2006	2005	
United States	252	229	2,153	16,176	20,513		13	26	125	1,181	1,288	
New England	10	30	780	2,837	3,804		_	1	11	46	70	
Connecticut Maine [†]	3 6	11 1	753 34	1,650 280	933 241		_	0 0	3 1	11 4	20 5	
Massachusetts	_	Ó	14	33	2,301		_	0	3	19	36	
New Hampshire	_	4	92	544	239		_	0	3	10	6	
Rhode Island Vermont [†]	1	0 1	93 15	235 95	37 53		_	0 0	8 1	1 1	2 1	
Mid. Atlantic	138	125	1,176	9,121	11,675		1	5	13	262	338	
New Jersey	_	22	173	1,918	3,311		_	0	3	28	75	
New York (Upstate) New York City	135	58 1	1,150 18	3,869 154	3,808 389		_	1 3	11 9	46 144	48 181	
Pennsylvania	3	40	235	3,180	4,167		1	ĭ	4	44	34	
E.N. Central	3	10	146	1,395	1,709		1	2	7	117	140	
Illinois Indiana		0	1 3	 21	127 30		<u> </u>	1 0	4 3	45 11	73 8	
Michigan	1	1	6	54	59		_	0	2	17	21	
Ohio	_	1	5	43	53		_	0	3	27	24	
Wisconsin	_	9	142	1,277	1,440		_	0	2	17	14	
W.N. Central lowa	53 —	5 1	169 8	771 87	899 91		1	0 0	32 1	60 2	46 8	
Kansas	_	0	2	4	3		_	0	2	7	7	
Minnesota Missouri	53 —	2 0	167 2	658 10	786 14		1	0 0	30 1	38 6	11 17	
Nebraska [†]	_	0	2	11	3		_	0	1	5	3	
North Dakota	_	0	3	_ 1			_	0	1 1	1 1	_	
South Dakota	45		1					0				
S. Atlantic Delaware	45 2	26 7	115 28	1,764 454	2,178 631		6	6 0	15 1	303 5	286 3	
District of Columbia	_	0	7	56	8		_	0	2	5	9	
Florida Georgia	4	1 0	5 1	53 7	44 6		4 1	1 1	4 6	59 78	58 47	
Maryland [†]	24	13	72	860	1,172		i	1	5	66	95	
North Carolina South Carolina [†]	_	0 0	4 2	29 18	44 19		_	0 0	8 2	28 9	30 10	
Virginia†	15	3	25	273	237		_	1	9	51	31	
West Virginia	_	0	44	14	17		_	0	1	2	3	
E.S. Central	1	0	3	33	35		_	0	3	22	29	
Alabama† Kentucky	1	0 0	3 2	13 7	3 5		_	0 0	2 1	9 4	6 10	
Mississippi	_	0	1	1	_		_	0	1	4	_	
Tennessee [†]	_	0	2	12	27		_	0	2	5	13	
W.S. Central Arkansas	_	0 0	3 1	18	76 4		_	2 0	31 1	83 2	117 6	
Louisiana	_	0	0	_	3		_	0	1	5	5	
Oklahoma Texas [†]	_	0 0	0 3	— 18	— 69		_	0 1	2 29	7 69	10 96	
Mountain	_	0	3	26	21		2	1	9	67	52	
Arizona	_	0	2	26 8	8		1	0	9	23	13	
Colorado	_	0	1	1			1	0	2	16	24	
Idaho† Montana†	_	0 0	2 0	6	_		_	0 0	1 1	1 2	_	
Nevada [†]	_	0	1	2	3		_	0	1	4	3	
New Mexico† Utah	_	0 0	1	2 6	3 2		_	0 0	1 2	4 17	3 7	
Wyoming	_	0	i	1	3		_	0	0		2	
Pacific	2	4	16	211	116		2	4	13	221	210	
Alaska California		0 4	1 15	3 192	4 81		_	0 3	4	23 146	6 155	
Hawaii	N N	0	15 0	192 N	81 N		_	0	10 2	146 8	155 18	
Oregon [†]	_	0	2	13	21		_	0	2	12	13	
Washington	_	0	3	3	10		_	0	5	32	18	
American Samoa C.N.M.I.	U U	0 0	0	U	U U		U U	0 0	0 0	U U	U U	
Guam	_	0	0	_	_		_	0	0	_	_	
Puerto Rico	N	0	0	N	N		_	0 0	1	1	4	
U.S. Virgin Islands		U	U		_		_	U	0	_	_	

Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-case incidence data for reporting year 2006 is provisional.

* Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending December 2, 2006, and December 3, 2005 (48th Week)*

(48th Week)*				Menir	ngococcal	disease, inv	asive									
		ı	All serog	roups			Sero	group u	ınknown				Pertu	ssis		
Reporting area	Current week	Prev 52 w Med	ious <u>eeks</u> Max	Cum 2006	Cum 2005	Current week	Previous 52 we Med		Cum 2006	Cum 2005	Current week		vious veeks Max	Cum 2006	Cum 2005	
United States	12	19	85	943	1,111	9	12	58	632	690	147	255	2,877	11,807	21,421	
New England Connecticut Maine [†] Massachusetts New Hampshire	_ _ _ _	1 0 0 0	3 2 1 2 2	42 10 6 15 6	67 14 2 30 12		0 0 0 0	2 2 1 2 2	28 3 4 15 6	22 1 2 5 12	12 — — — 4	24 1 1 16 2	83 5 11 43 36	1,071 45 89 594 180	1,409 71 53 1,059 105	
Rhode Island Vermont [†]	=	0	1	2	4 5	_	0	0	-	2	8	0 2	17 14	58 105	36 85	
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	3 — — — 3	2 0 0 1 1	13 2 7 4 5	119 16 — 58 45	142 31 38 24 49	3 - - - 3	2 0 0 1 0	11 2 5 4 5	115 16 — 58 41	110 31 14 24 41	25 — 20 — 5	36 3 15 1	137 13 123 8 26	1,690 185 803 64 638	1,236 175 486 102 473	
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	1 - - 1	2 0 0 0 1	11 4 5 3 4 2	111 18 22 20 43 8	153 33 18 34 43 25	_ _ _ _ _	1 0 0 0 1	6 4 1 1 3 2	78 18 8 9 35	121 33 8 18 37 25	27 — 2 7 18	38 5 4 9 12	133 23 75 39 29	1,760 231 223 572 566 168	3,626 876 312 295 1,090 1,053	
W.N. Central lowa Kansas Minnesota Missouri Nebraska† North Dakota South Dakota	_ _ _ _ _	1 0 0 0 0 0	4 2 1 2 2 2 1	56 18 2 13 14 6 1	79 15 9 16 28 6 1	_ _ _ _	0 0 0 0 0 0 0 0	2 1 1 1 1 1 1 1	18 5 2 4 2 4 1	33 1 9 6 13 3	7 7 — —	24 6 6 0 6 2 0	552 32 25 485 42 9 25	1,117 256 290 161 274 90 26 20	3,712 1,048 474 1,062 532 278 139 179	
S. Atlantic Delaware District of Columbia Florida Georgia Maryland† North Carolina South Carolina† Virginia† West Virginia	3 - 2 - 1 -	3 0 0 1 0 0 0	14 1 1 6 3 2 11 2 4 2	177 4 2 67 15 13 31 20 16 9	208 4 5 76 17 22 32 13 33 6	2 — 1 — 1 —	1 0 0 0 0 0 0	7 1 1 5 3 1 3 2 1 0	75 4 2 24 15 3 11 9 7	95 4 4 32 17 5 9 8 14 2	5 3 2	18 0 0 4 0 3 0 3 2	46 1 3 9 3 9 22 11 27 9	925 3 6 197 25 121 177 166 187 43	1,337 15 8 190 47 195 118 389 329 46	
E.S. Central Alabama [†] Kentucky Mississippi Tennessee [†]	1 - - 1	1 0 0 0	4 1 2 1 2	41 6 11 4 20	54 5 18 7 24	1 - - 1	1 0 0 0	4 1 2 1 2	33 4 11 4 14	43 3 18 7 15	1 1 — —	6 1 1 1 3	27 18 5 4 10	355 109 54 41 151	486 79 146 60 201	
W.S. Central Arkansas Louisiana Oklahoma Texas†	_ _ _ _	1 0 0 0	23 3 2 4 16	56 10 6 11 29	103 15 30 14 44	_ _ _ _	0 0 0 0	6 2 1 0 4	24 7 3 — 14	26 3 7 2 14	_ _ _ _	15 1 0 0 12	360 21 2 124 215	678 75 13 19 571	2,238 288 51 3 1,896	
Mountain Arizona Colorado Idaho† Montana† Nevada† New Mexico† Utah Wyoming	_ _ _ _ _ _	1 0 0 0 0 0 0	5 3 2 1 1 1 1 2	65 17 20 4 5 4 6 5	82 31 17 6 — 12 5 11	_ _ _ _ _ _	0 0 0 0 0 0	4 2 1 1 1 0 1 0 2	24 10 2 3 2 — 3 — 4	23 10 — 5 — 2 4 2	43 25 9 — — 1 8	49 7 13 1 2 0 2 14 1	230 177 40 8 9 9 8 39	2,408 455 712 84 108 55 112 810 72	3,805 911 1,269 201 580 50 180 564 50	
Pacific Alaska California Hawaii Oregon [†] Washington	4 -3 - - 1	5 0 3 0 1	29 1 14 2 7 25	276 3 170 9 62 32	223 4 139 11 50 19	3 - 3 - -	5 0 3 0 1	25 1 14 2 4 11	237 3 170 9 43 12	217 4 139 6 50 18	27 — 20 — — 7	30 1 21 1 2 5	1,334 15 1,136 6 8 195	1,803 63 1,278 78 98 286	3,572 135 1,840 160 616 821	
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U - -	0 0 0 0	0 0 0 0	_ _ _	 1 7 	U - -	0 0 0 0	0 0 0 0	U — —	U U 1 7	U - -	0 0 0 0	0 0 0 1 0	U - 2 -	U U 2 6	

Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to* Incidence data for reporting year 2006 is provisional.

† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending December 2, 2006, and December 3, 2005 (48th Week)*

(48th Week)*	Rabies, animal Rocky Mountain spotted fever						0.1								
			, .	mal		Roc			tted fever				almonello	osis	
	Current	Prev 52 w		Cum	Cum	Current	Prev 52 w		Cum	Cum	Current		vious weeks	Cum	Cum
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	week	Med	Max	2006	2005
United States	36	119	236	5,774	5,496	7	38	246	1,991	1,662	655	779	2,291	38,635	40,793
New England Connecticut	4	12 3	26 14	626 198	664 195	1	0	2	3	8	7	23 0	462 454	1,706 454	2,047 444
Maine [†]	_	2	8 17	112 178	58 317	N	0	0	N 1	N 6	_	2 16	10 53	110 782	160 1,087
Massachusetts New Hampshire	1	1	5	51	12	_	0	1	1	1	3	3	25	202	170
Rhode Island Vermont [†]	_	0 1	3 5	24 63	27 55	1	0	2 0	1	1 —	1 3	0 1	17 6	84 74	95 91
Mid. Atlantic	9	27	61	1,424	937	_	1	6	80	94	44	84	272	4,700	4,774
New Jersey New York (Upstate)	N 9	0 10	0 24	N 513	N 528	_	0 0	1 2	7 5	29 1	— 31	14 24	48 233	803 1,207	924 1,131
New York City Pennsylvania	_	0 16	5 45	35 876	28 381	_	0 1	3 3	23 45	7 57	1 12	22 29	51 67	1,147 1,543	1,144 1,575
E.N. Central	_	2	18	163	168	_	0	6	42	41	69	102	187	4,670	5,350
Illinois Indiana	_	0	7 2	46 11	50 11	_	0	2 1	5 8	11 1	 17	22 15	51 67	1,005 801	1,753 589
Michigan	_	1	5	48	37	_	0	1	3	6	9	18	35	891	875
Ohio Wisconsin	N	0 0	9 0	58 N	70 N	_	0 0	4 1	25 1	21 2	43	23 17	56 27	1,203 770	1,237 896
W.N. Central lowa	2	6 1	20 7	299 57	306	_	2	15 1	206 5	153 7	27 2	44 8	107 26	2,452 423	2,409 390
Kansas	1	1	5	78	74	_	0	1	1	5	7	7	16	345	339
Minnesota Missouri	1	0 1	6 6	40 65	68 70	_	0 2	2 11	4 171	2 127	18	11 14	60 35	668 693	525 752
Nebraska [†]	_	0	0	_	_	_	0	5	25	7	_	3	9	179	212
North Dakota South Dakota	_	0 1	7 4	24 35	30 64	_	0	1 0	_	5	_	0 2	46 7	28 116	38 153
S. Atlantic Delaware	19	38 0	180 0	2,040	1,985	5	20 0	94 3	1,119 21	833 7	210	219 3	394 10	10,490 142	11,932 117
District of Columbia	=	0	Ō	_	=	=	Ö	1	1	2	1	1	4	60	53
Florida Georgia	_	0 5	164 24	164 213	201 245	1 1	0 1	3 5	21 49	13 85	134 41	95 31	176 72	4,452 1,646	4,987 1,853
Maryland [†] North Carolina	_ 7	7 9	13 22	318 488	362 449	2	1 17	6 87	74 817	69 468	10 10	12 33	29 130	674 1,531	768 1,556
South Carolina†	_	3	11	164	209	_	0	5	33	71	7	18	51	938	1,353
Virginia [†] West Virginia	12 —	11 2	27 7	585 108	454 65	1	1 0	13 2	100 3	111 7	7 —	20 2	57 19	913 134	1,068 177
E.S. Central Alabama†	_	4 1	16 8	250 79	143 75	_	5 1	31 10	369 115	287 72	92 82	52 16	150 72	2,943 1,101	2,788 668
Kentucky	_	0	4	29	17	_	0	1	3	3	2	8	23	411	462
Mississippi Tennessee [†]	_	0 2	2 9	4 138	5 46	_	0 3	1 22	4 247	18 194	8	11 15	42 32	709 722	873 785
W.S. Central	_	11	34 5	562	819	_	1	161	115	212	18	74	922	3,866	4,063
Arkansas Louisiana	_	0 0	0	31 —	33	_	0 0	10 1	51 4	124 6	18	15 12	47 42	884 740	689 870
Oklahoma Texas†	_	1 10	9 29	60 471	75 711	_	0 0	154 4	36 24	52 30	_	8 32	48 839	462 1,780	382 2,122
Mountain	_	3	27	202	266	_	0	6	49	32	52	50	88	2,370	2,256
Arizona Colorado	_	2	10 0	132	165 18	_	0	6 1	10 2	17 4	32 14	17 12	67 30	806 579	635 548
Idaho [†] Montana [†]	_	0	25 2	25 14	12 15	_	0	3 2	14 2	3 1	3	3 2	9 10	164 119	144 132
Nevada [†]	_	0	1	2	14	_	0	0	_	_	_	3	20	174	186
New Mexico† Utah	_	0	2 1	10 11	10 15	_	0	2 2	8 6	4	3	4 5	15 15	226 259	238 291
Wyoming	_	Ö	2	8	17	_	Ö	1	7	3	_	1	4	43	82
Pacific Alaska	2	4 0	12 4	208 15	208 1	1	0	1 0	8	2	136	111 1	426 7	5,438 67	5,174 57
California	2	3	11	168	200	1	0	1	6	_	122	90	292	4,285	3,963
Hawaii Oregon†	_	0	0 4	 25	7	_	0	0 1		_	1	5 8	18 16	246 384	274 388
Washington	U	0	0	U	U	N	0	0	N	N	13	8	124	456	492
American Samoa C.N.M.I.	U U	0	0	U U	U	U U	0	0	U U	U U	U U	0	0	U	7 U
Guam	_	0	Ō	_	_	_	0	0	— N	— N	- 3	2	3	_	40
Puerto Rico U.S. Virgin Islands	_	1 0	6 0	68 —	63 —	<u>N</u>	0	0 0	N —	N	<u>3</u>	4 0	35 0	233	604

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: No U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-one * Incidence data for reporting year 2006 is provisional.

† Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending December 2, 2006, and December 3, 2005 (48th Week)*

(48th Week)*	Shiga	a toxin-pı	roducing	E. coli (S	ΓEC) [†]		Sł	igellosi	s		Streptococcal disease, invasive, group A					
	Current	Prev	ious eeks	Cum	Cum	Current		ious eeks	Cum	Cum	Current	Prev 52 w		Cum	Cum	
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	week	Med	Max	2006	2005	
United States	39	52	297	2,603	3,041	287	256	1,013	12,429	14,238	57	92	282	4,363	4,154	
New England Connecticut	_	3 0	80 79	254 79	211 58	1	3	68 62	223 62	306 54	 U	4 0	15 2	185 U	266 95	
Maine§ Massachusetts	_	0	8	43 82	29 83	_	0	2 11	3 128	15 183		0	2 6	17 101	14 121	
New Hampshire	_	0	3	25	16	1	0	4	11	17	_	0	9	45	17	
Rhode Island Vermont [§]	_	0 0	2 2	8 2	7 18	_	0	3 2	13 6	20 17	_	0	3 2	8 14	9 10	
Mid. Atlantic	2	4	107	190	343	6	16	72	774	1,175	13	18	43	842	818	
New Jersey New York (Upstate)	_	0	3 103	3 10	73 130	6	3 4	34 60	242 214	294 256	9	2 5	8 32	122 286	173 228	
New York City Pennsylvania	_	0 0	4 4	33 8	17 123	_	5 1	13 6	235 83	394 231	4	3 6	8 13	141 293	161 256	
E.N. Central	8	10	56	603	609	9	20	37	926	1,110	4	14	44	724	833	
Illinois Indiana	_	1 1	7 8	75 78	136 68	1	7 2	18 18	316 151	378 172	1	3 2	11 11	144 106	276 95	
Michigan Ohio	1 7	1 3	7 18	87 186	87 165	1 7	3	8 14	142 183	225 118	2 1	4 4	12 19	202 220	196 179	
Wisconsin	_	2	39	177	153	_	3	9	134	217	_	1	4	52	87	
W.N. Central lowa	<u>8</u>	9 2	33 8	506 115	506 95	17 —	34 2	77 10	1,580 104	1,615 95	7 N	5 0	57 0	319 N	264 N	
Kansas Minnesota	<u> </u>	0 3	4 27	26 225	53 165	2 14	2	20 23	134 217	239 87	<u> </u>	1 0	5 52	51 149	38 101	
Missouri Nebraska [§]	_	1	10 8	82 55	94 60	<u></u>	9	69 14	613 119	954 143	- 1	1	5 4	71 29	65 22	
North Dakota	_	0	15	_	8	_	0	18	103	4	_	0	5	11	13	
South Dakota S. Atlantic	9	0 9	5 39	49 448	31 387	— 108	6 57	22 142	290 3.115	93 2,275	18	0 21	1 44	8 1.067	25 866	
Delaware	_	0	2	11	9	_	0	2	10	11	_	0	2	10	6	
District of Columbia Florida	2	0 2	1 29	3 87	1 87	1 50	0 27	2 76	17 1,473	15 1,122	2 1	0 5	2 16	17 274	11 235	
Georgia Maryland [§]	2 4	2 1	6 8	84 97	49 73	55 1	19 2	72 10	1,165 122	626 97	9 5	4 4	12 12	231 189	188 166	
North Carolina South Carolina [§]	2	2	7 2	106 9	60 12	_	1 1	21 9	151 72	184 97	1	0 1	26 6	149 54	118 33	
Virginia [§] West Virginia	_	0 0	8 5	<u>-</u> 12	92 4	1	2 0	9	101	122 1	_	2 0	11 6	116 27	87 22	
E.S. Central	_	1	12	93	173	53	13	80	874	1,141	1	3	11	181	168	
Alabama [§] Kentucky	_2	0 1	5 12	41 93	29 74	45 1	4	72 15	407 227	211 306	N	0	0 5	N 35	N 32	
Mississippi Tennessee [§]	_	0	0		8 62	- 7	1 2	9	86 154	95 529	_ 1	0	0	— 146	136	
W.S. Central	_	1	52	24 76	106	7 29	36	596	1,677	3,421	3	3 7	58	338	295	
Arkansas Louisiana	_	0 0	7 1	33	13 21	2	2	9 25	115 132	58 135		0	5 2	25 8	21	
Oklahoma	_	0	17	43	27	_	2	286	125	608	_	2	14	93	110	
Texas§ Mountain	1 9	2 5	44 16	108 303	45 299	27 27	30 23	308 86	1,305 1,350	2,620 897	3 11	4 11	43 77	212 588	164 538	
Arizona	8	2	13	124	30	17	11	34	673	475	3	6	57	314	227	
Colorado Idaho [§]	1	1 1	8 7	102 81	81 50	7	4 0	15 3	232 15	159 17	7	3 0	8 2	130 8	164 3	
Montana [§] Nevada [§]	_	0 0	0 5	 22	16 24	_	0 1	13 20	54 103	5 62	_	0 0	0	_	_	
New Mexico [§] Utah	 5	0 1	1 14	4 120	24 64		2 1	15 6	163 78	130 44	_ 1	1	7 7	67 65	79 60	
Wyoming	_	0	3	18	10	_	Ö	8	32	5	<u>.</u>	Ö	1	4	5	
Pacific Alaska	3	2	50 0	130	407	37	39 0	148 2	1,910 9	2,298 11	_	3 0	9	119	106	
California Hawaii	_	0	18 3	— 18	142 13	36	31 1	104 4	1,608 43	1,998 32	_	0	0	— 119	 106	
Oregon [§]	_	2	14	107	152	_	1	31	115	123	N	0	0	N	N	
Washington American Samoa	3 U	2	32 0	112 U	100 U	1 U	2	43 0	135 U	134 7	N U	0	0	N U	N U	
C.N.M.I.	U	0	0	U	U	U	0	0	U	U	U	0	0	U	U	
Guam Puerto Rico	_	0	0	_		_	0	3	13	20 9	N	0	0	N	N	
U.S. Virgin Islands		0	0		_		0	0				0	0			

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: No N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

[†] Incidence data for reporting year 2006 is provisional.
† Includes *E. coli* O157:H7; Shiga toxin positive, serogroup non-0157; and Shiga toxin positive, not serogrouped. Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending December 2, 2006, and December 3, 2005 (48th Week)*

Peporting area Pero Per	enpox)					
Reporting area Meek Meek		Varicella (chickenpox)				
Reporting area Week Med Max 2006 2005 Week Med Max 2006 2005 Week Med Max Max Med Max Max Med Max Max Med Max Max Med Med Med Max Med Med Med Max Med Med			_	_		
New England				Cu 20		
Connecticut U 0 7 U 88 3 0 11 51 46 U 0 55 Mainet — 0 2 9 N — 0 2 8 1 — 2 20 Massachusetts — 0 5 — 97 2 2 6 109 115 — 0 54 New Hampshire — 0 0 — — 1 0 2 112 15 6 6 47 Rhode Island — 0 1 1 1 38 12 50 Mid. Attantic 1 3 15 162 191 12 21 35 1,027 951 119 102 183 New Jork City N 0 0 N N — 3 8 150 126 — 0 0 New Yo	38,520 27,	38,520 27	27,0	27,0		
Mainer				4,9		
Massachusetts — 0 5 — 97 2 2 6 109 115 — 0 54 New Hampshire — 0 0 — — 1 0 2 12 15 6 6 47 Rhode Island — 0 11 13 18 2 0 2 13 22 — 0 0 Vermont** — 0 2 14 11 — 0 1 2 1 38 12 50 Mid. Atlantic 1 3 15 162 191 12 21 35 1,027 951 119 102 183 New Jork City U 0 0 W W N N — 3 14 139 72 — 0 0 Pennsylvania 1 2 9 103 119 1 5 <t< td=""><td></td><td></td><td></td><td>1,5</td></t<>				1,5		
Rhode Island	94 2,	94 2	2,	2,		
Mid. Atlantic 1 3 15 162 191 12 21 35 1,027 951 119 102 183 New Jersey N 0 0 N N — 3 8 150 126 — 0 0 New York (Upstate) — 1 10 59 72 3 3 14 139 72 — 0 0 New York (City U 0 0 U U 0 </td <td>_</td> <td>_</td> <td></td> <td>3</td>	_	_		3		
New Jersey				(
New York City	4,545 4, —	4,545 4	4,	4,5		
Pennsylvania	_					
Illinois			4,5	4,5		
Indiana			5,5	5,5		
Ohio 2 6 32 333 335 3 3 8 177 200 236 130 420 Wisconsin N 0 0 N N 2 1 4 63 35 — 11 52 W.N. Central 1 1 191 102 43 3 5 12 243 237 16 28 98 Iowa N 0 0 N N — 0 3 18 8 N 0 0 Kansas N 0 0 N N 1 0 3 24 17 16 28 98 Minnesota — 0 1 0 3 24 17 16 3 24 Minnesota — 0 191 60 — — 0 2 29 68 — 0 0	68 475					
Wisconsin N 0 0 N N 2 1 4 63 35 — 11 52 W.N. Central 1 1 191 102 43 3 5 12 243 237 16 28 98 lowa N 0 0 N N — 0 3 18 8 N 0 0 Kansas N 0 0 N N 1 0 3 24 17 16 3 24 Minnesota — 0 191 60 — — 0 2 29 68 — 0 0 Missouri — 1 3 39 35 1 3 8 155 138 — 22 82 Nebraska† — 0 1 1 2 1 0 1 4 4 4				3,5 1,4		
Iowa				1,-		
Kansas N 0 0 N N 1 0 3 24 17 16 3 24 Minnesota — 0 191 60 — — 0 2 29 68 — 0 0 Missouri — 1 3 39 35 1 3 8 155 138 — 22 82 Nebraska† — 0 1 1 2 1 0 1 4 4 — 0 0 North Dakota — 0 0 — 3 — 0 1 1 1 — 0 17 South Dakota 1 0 1 2 3 — 0 3 12 1 — 0 17 South Dakota 1 0 1 2 3 — 0 3 12 1 — 1 </td <td></td> <td></td> <td>(</td> <td>6</td>			(6		
Missouri — 1 3 39 35 1 3 8 155 138 — 22 82 Nebraska† — 0 1 1 2 1 0 1 4 4 — 0 0 North Dakota — 0 0 — 3 — 0 1 1 1 — 0 17 South Dakota 1 0 1 2 3 — 0 3 12 1 — 0 17 S. Atlantic 18 25 53 1,195 999 21 42 186 1,948 1,973 97 88 860 Delaware — 0 0 — 3 — 0 2 17 10 — 1 6 District of Columbia — 0 3 26 15 2 2 9 117 102	N 311					
Nebraska† — 0 1 1 2 1 0 1 4 4 — 0 0 North Dakota — 0 0 1	1,196	 1 196	4	2		
South Dakota 1 0 1 2 3 — 0 3 12 1 — 1 10 S. Atlantic 18 25 53 1,195 999 21 42 186 1,948 1,973 97 88 860 Delaware — 0 0 — 3 — 0 2 17 10 — 1 6 District of Columbia — 0 3 26 15 2 2 9 117 102 1 0 5 Florida 13 14 36 665 536 5 15 23 676 657 20 0	´ —	· —				
Delaware — 0 0 — 3 — 0 2 17 10 — 1 6 District of Columbia — 0 3 26 15 2 2 9 117 102 1 0 5 Florida 13 14 36 665 536 5 15 23 676 657 20 0 0	45 78			1		
District of Columbia — 0 3 26 15 2 2 9 117 102 1 0 5 Florida 13 14 36 665 536 5 15 23 676 657 20 0 0			2,4	2,4		
	63 46					
Georgia 5 6 29 401 334 4 6 147 355 448 — 0 0	20					
Maryland † — 0 0 — — 5 5 19 265 292 — 0 4	11	11				
North Carolina N 0 0 N N 2 5 17 274 251 — 0 0 South Carolina † — 0 0 — — 1 1 6 63 81 22 18 53	1,005		į	Ę		
Virginia [†] N 0 0 N N 2 3 17 176 129 26 29 812 West Virginia — 1 14 103 111 — 0 1 5 3 28 26 70	1,556	1,556	7	1,0		
E.S. Central 2 3 13 135 174 13 13 26 676 447 3 1 70				1,0		
Alabama † N 0 0 N N 7 5 19 295 149 3 1 70	132	132		2		
Kentucky — 0 2 — 31 2 1 8 65 50 N 0 0 Mississippi — 0 0 — 1 — 1 7 69 46 — 0 1	N 2					
Tennessee [†] 2 3 13 135 142 4 5 13 247 202 N 0 0	N					
W.S. Central — 0 5 20 110 12 29 55 1,457 1,164 251 188 1,757 Arkansas — 0 3 12 14 1 1 6 75 47 72 11 110	10,351 6, 887		6,3	6,3		
Louisiana — 0 4 8 96 4 4 27 268 263 — 0 8 Oklahoma N 0 0 N N — 1 6 66 37 — 0 0	48			1		
Texas † N 0 0 N N 7 22 36 1,048 817 179 170 1,647			6,	6,		
Mountain — 2 9 90 50 7 8 25 381 393 89 58 137	2,618 2,	2,618 2	2,4	2,4		
Arizona N 0 0 N N 7 3 16 171 158 — 0 0 Colorado N 0 0 N N — 1 3 44 44 30 31 76		1,388 1	1,6	1,6		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	<u> </u>	<u> </u>				
Nevada † — 0 0 — — — 1 12 95 102 — 0 0	_	_				
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$				2		
Wyoming — 1 4 42 25 — 0 0 — — 0 11	53	53				
Pacific — 0 0 — — 15 35 51 1,556 1,661 — 0 0 Alaska — 0 0 — — 0 4 9 6 — 0 0	_	_				
California N 0 0 N N 4 29 43 1,342 1,469 — 0 0						
Oregon † N 0 0 N N 6 0 3 24 36 N 0 0	N N	N				
Washington N 0 0 N N 5 2 10 164 139 N 0 0	N					
American Samoa — 0 0 — — U 0 0 U U U 0 0 C.N.M.I. — 0 0 — U U U U U 0 0	U U					
Guam — 0 0 — — — 0 0 — 3 — 3 5 Puerto Rico N 0 0 N N 5 3 10 130 206 5 7 47		321		6		
U.S. Virgin Islands — 0 0 — — 0 0 — — 0 0		UL 1	,	,		

Cum: Cumulative year-to-date counts.

Med: Median.

Max: Maximum.

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-t* Incidence data for reporting year 2006 is provisional.

Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 2, 2006, and December 3, 2005 (48th Week)*

(48th Week)*					West Nile vire	us dispasat					
			Neuroinva	sive	west mile viii	us disease	No	n-neuroin	vasive		
			rious	5140		-		ious	1140110		
Reporting area	Current week		reeks Max	Cum 2006	Cum 2005	Current week		reeks Max	Cum 2006	Cum 2005	
United States	—	1	176	1,388	1,191	— WCCK	1	383	2,454	1,683	
New England	_	0	3	9	9	_	0	2	3	4	
Connecticut	_	0	3	7	4	_	0	1	2	2	
Maine§ Massachusetts	_	0	0 1		4	_	0 0	0 1	_ 1		
New Hampshire	_	0	Ö	_	_	_	0	Ö		_	
Rhode Island	_	0	0	_	1	_	0	0	_	_	
Vermont§	_	0	0	_	_	_	0	0	_	_	
Mid. Atlantic New Jersey	_	0 0	11 2	26 2	47 3	_	0 0	4 1	10 2	22 3	
New York (Upstate)	_	Ö	5	8	19	_	Ö	1	3	5	
New York City	_	0 0	4 2	8 8	11		0 0	2	4 1	3	
Pennsylvania					14			1		11	
E.N. Central Illinois	_	0 0	43 21	236 116	259 137	_	0 0	22 19	99 70	156 115	
Indiana	_	0	7	26	11	_	0	2	7	12	
Michigan	_	0	10	47	54	_	0	1	2	8	
Ohio Wisconsin	_	0	11 2	36 11	46 11	_	0 0	3 2	11 9	15 6	
W.N. Central	_	0	35	216	169	_	0	79	477	463	
Iowa	_	0	3	21	14	_	0	4	13	23	
Kansas	_	0	3	17	17	_	0	3	13	N	
Minnesota Missouri	_	0	6 13	30 47	18 17	_	0 0	7 2	35 12	27 13	
Nebraska§	_	0	9	43	55	_	0	37	212	133	
North Dakota South Dakota	_	0	5 7	20 38	12 36	_	0 0	28 22	117 75	74 193	
	_										
S. Atlantic Delaware	_	0 0	2 0	14	34 1	_	0 0	4 0	7	29 1	
District of Columbia	_	0	0	_	3	_	0	1	1	2	
Florida Georgia	_	0 0	1 1	3 2	10 9	_	0 0	0 3	 5	11 11	
Maryland [§]	_	0	2	7	4	_	0	1	1	'1	
North Carolina	_	0	0	_	2	_	0	0	_	2	
South Carolina [§] Virginia [§]	_	0 0	1 0	1	5 —	_	0 0	0 0	_	_ 1	
West Virginia	_	Ö	ĭ	1	_	N	Ő	ő	N	Ň	
E.S. Central	_	0	14	109	65	_	0	16	94	38	
Alabama§	_	0	2	7	6	_	0	0	_	4	
Kentucky Mississippi	_	0	0 10	— 87	5 39	_	0 0	1 16	1 91	31	
Tennessee§	_	Ö	4	15	15	_	Ö	2	2	3	
W.S. Central	_	0	59	350	157	_	0	26	208	150	
Arkansas	_	0	4	23	13	_	0	2	5	15	
Louisiana Oklahoma	_	0	14 6	88 27	 17	_	0 0	9 4	81 18	54 14	
Texas§	_	Ö	38	212	127	_	Ö	15	104	67	
Mountain	_	0	61	342	145	_	0	222	1,321	240	
Arizona Colorado	_	0 0	9 10	48 63	52 21	_	0 0	12 51	58 269	61 85	
Idaho§	_	0	30	111	3	_	0	151	269 752	10	
Montana [§]	_	0	3	12	8	_	0	7	21	17	
Nevada [§] New Mexico [§]	_	0	9 1	34 3	14 20	_	0 0	13 1	75 5	17 13	
Utah	_	0	8	56	21	_	0	17	101	31	
Wyoming	_	0	7	15	6	_	0	8	40	6	
Pacific	_	0	15	86	306	_	0	45	235	581	
Alaska California	_	0 0	0 15	— 79	305	_	0 0	0 33	 182	— 575	
Hawaii	_	0	0	_	_	_	0	0	_	-	
Oregon§	_	0	2	7	1	_	0	12	50	6	
Washington	_	0	0	_	_	_	0	2	3	_	
American Samoa C.N.M.I.	U U	0	0	U U	U U	U U	0 0	0 0	U U	U U	
Guam	_	0	0	_	_	_	0	0	_	_	
Puerto Rico	_	0	0	_	_	_	0	0	_	_	
U.S. Virgin Islands		U	U				U	U		_	

C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

* Incidence data for reporting year 2006 is provisional.

Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (proposed) (ArboNET Surveillance).

Scontains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE III. Deaths in 122 U.S. cities.* week ending December 2, 2006 (48th Week)

TABLE III. Deaths			auses, b							All	causes, b	y age (y	ears)		
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	P&I [†] Total	Reporting Area	All Ages	<u>≥</u> 65	45-64	25-44	1-24	<1	P&I [†] Total
New England	554	380	118	31	11	14	44	S. Atlantic	1,138	712	297	75	33	21	69
Boston, MA	128	70	30	15	6	7	7	Atlanta, GA	U	U	U	U	U	U	U
Bridgeport, CT	39	30	4	3	1	1	6	Baltimore, MD	139	80	45	9	3	2	15
Cambridge, MA	15	11	4	_	_	_	2	Charlotte, NC	132	82	34	10	4	2	10
Fall River, MA	18 77	13 50	4 21	1 4	_	_	1 8	Jacksonville, FL	183 65	105	55 16	19 5	4 2	1	8 5
Hartford, CT Lowell, MA	34	24	7	1	1	1	5	Miami, FL Norfolk, VA	48	41 35	16 8	3	1	1	3
Lvnn. MA	10	6	3	1			_	Richmond, VA	63	39	19	4		1	4
New Bedford, MA	24	18	6		_	_	1	Savannah, GA	77	47	18	7	3	2	2
New Haven, CT	U	Ü	Ü	U	U	U	Ú	St. Petersburg, FL	67	36	20	3	3	5	5
Providence, RI	70	49	20	_	1	_	6	Tampa, FL	244	175	46	9	9	5	12
Somerville, MA	_	_	_	_	_	_	_	Washington, D.C.	101	56	33	6	4	2	1
Springfield, MA	53	41	7	3	_	2	5	Wilmington, DE	19	16	3	_	_	_	4
Waterbury, CT	31	25	5	1	_	_	2	E.S. Central	804	526	186	53	17	22	54
Worcester, MA	55	43	7	2	2	1	1	Birmingham, AL	204	134	51	8	4	7	17
Mid. Atlantic	2,233	1,553	476	129	31	42	122	Chattanooga, TN	95	70	13	4	3	5	6
Albany, NY	48	29	16	1	1	1	3	Knoxville, TN	104	67	28	7	2	_	6
Allentown, PA	29	24	3	2	_	_	3	Lexington, KY	69	44	15	8	1	1	6
Buffalo, NY	95	66	22	5	1	1	11	Memphis, TN	78	51	18	6	2	1	7
Camden, NJ	35	19	10	1	1	4	1	Mobile, AL	41	29	7	5	_	_	1
Elizabeth, NJ	15	9	3	2	1	_	_	Montgomery, AL	50	35	13	2	_	_	1
Erie, PA	58	49	6	1 2	_	2	3	Nashville, TN	163	96	41	13	5	8	10
Jersey City, NJ New York City, NY	22 1,149	12 785	8 264	71	14	14	2 60	W.S. Central	1,545	991	345	116	51	42	87
Newark, NJ	32	14	10	6	14	14	1	Austin, TX	111	69	26	10	4	2	11
Paterson, NJ	23	14	8	1				Baton Rouge, LA	35	20	_	_	10	5	2
Philadelphia, PA	272	175	58	22	9	8	13	Corpus Christi, TX	69	48	15	4	2	_	6
Pittsburgh, PA§	29	20	5	3	_	_	_	Dallas, TX	243	152	54	22	6	9	12
Reading, PA	35	31	1	2	_	1	1	El Paso, TX	60	44	11	4	_	1	2
Rochester, NY	196	151	35	2	2	6	15	Fort Worth, TX	120	78	32	6	1	3	9
Schenectady, NY	23	18	3	1	1	_	2	Houston, TX Little Rock, AR	381 87	240 56	91 17	36 5	10 3	4 6	15 5
Scranton, PA	41	30	9	1	_	1	1	New Orleans, LA	Ü	U	Ü	Ü	Ü	Ü	U
Syracuse, NY	60	49	8	_	_	3	3	San Antonio, TX	274	177	58	20	11	8	18
Trenton, NJ	35	28	5	2	_	_	1	Shreveport, LA	88	60	19	3	2	4	4
Utica, NY	14	10	_	4	_	_	1	Tulsa, OK	77	47	22	6	2	_	3
Yonkers, NY	22	20	2	_	_	_	1	Mountain	990	627	228	80	33	22	55
E.N. Central	2,189	1,463	499	126	47	54	139	Albuquerque, NM	141	94	27	12	5	3	10
Akron, OH	73	50	17	4	1	1	2	Boise, ID	47	37	9	_	_	1	3
Canton, OH	40	30	6	3	_	1	2	Colorado Springs, CO	77	49	15	5	4	4	4
Chicago, IL Cincinnati, OH	327 100	196 59	98 28	19 5	9 2	5 6	23 12	Denver, CO	75	40	21	7	3	4	1
Cleveland, OH	229	183	34	3	1	8	16	Las Vegas, NV	204	126	55	13	5	5	12
Columbus, OH	221	147	48	13	6	7	12	Ogden, UT	30	18	8	3	1	_	3
Dayton, OH	144	114	20	7	1	2	7	Phoenix, AZ	146	75	40	21	8	2	7
Detroit, MI	197	103	60	19	9	6	9	Pueblo, CO	35	22	8	2	3	_	3
Evansville, IN	62	46	14	1	_	1	6	Salt Like City, UT	113 122	75 91	25 20	9 8	3 1	1 2	7 5
Fort Wayne, IN	69	51	9	6	3	_	5	Tucson, AZ		91	20	0	'		
Gary, IN	16	6	7	3	_	_	1	Pacific	1,479	1,036	317	64	32	30	116
Grand Rapids, MI	52	37	10	. 1	1	3	3	Berkeley, CA	17	11	4	_	_	2	1
Indianapolis, IN	207	129	58	13	2	5	12	Fresno, CA	126	96	20	6	2	2	9
Lansing, MI	70	48	16	4	_	2	2	Glendale, CA	U	U	U	U	U	U	U
Milwaukee, WI	22	16	3	1	_	2	_	Honolulu, HI	76 75	46	25	3	2	_	6
Peoria, IL Rockford, IL	58 64	45 31	9 10	3 15	1 6	_	9	Long Beach, CA	75 U	54 U	9 U	6 U	4 U	2 U	9 U
South Bend, IN	80	59	17	2	1	1	<u> </u>	Los Angeles, CA Pasadena, CA	27	21	5	1	U	_	2
Toledo, OH	105	71	26	4	4		8	Portland, OR	146	101	31	6	3	5	10
Youngstown, OH	53	42	9			2	5	Sacramento, CA	251	173	59	11	5	3	24
_				20	10			San Diego, CA	168	112	37	9	2	8	19
W.N. Central Des Moines, IA	538	347	131	29	18	13	41	San Francisco, CA	103	76	23	1	1	2	9
Duluth, MN	38	28	6	3	_	1	2	San Jose, CA	148	106	34	3	3	2	12
Kansas City, KS	39	23	10	2	4		1	Santa Cruz, CA	39	26	9	2	2	_	1
Kansas City, MO	75	48	17	5	3	2	5	Seattle, WA	136	85	36	8	4	3	5
Lincoln, NE	37	29	8	_	_	_	1	Spokane, WA	63	55	3	4	1	_	6
Minneapolis, MN	82	44	27	4	4	3	6	Tacoma, WA	104	74	22	4	3	1	3
Omaha, NE	100	63	21	7	5	4	12	Total	11,470**	7,635	2,597	703	273	260	727
St. Louis, MO	Ü	Ü	Ü	Ú	Ŭ	Ü	Ü		,	,	,				
St. Paul, MN	66	50	11	3	_	2	8	l							

U: Unavailable. —:No reported cases.

* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.


† Pneumonia and influenza.

§ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

¶ Because of Hurricane Katrina, weekly reporting of deaths has been temporarily disrupted.

** Total includes unknown ages.

FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals December 2, 2006, with historical data



Notifiable Disease Data Team and 122 Cities Mortality Data Team

Patsy A. Hall

Deborah A. Adams Rosaline Dhara Willie J. Anderson Vernitta Love Lenee Blanton Pearl C. Sharp

^{*} No rubella cases were reported for the current 4-week period yielding a ratio for week 48 of zero (0).

† Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, send an e-mail message to listserv@listserv.edc.gov. The body content should read SUBscribe mmwrtoc. Electronic copy also is available from CDC's Internet server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at ftp://ftp.cdc.gov/pub/publications/mmwr. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Data are compiled in the National Center for Public Health Informatics, Division of Integrated Surveillance Systems and Services. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to *www.mmwrq@cdc.gov*.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in MMWR were current as of the date of publication.

☆U.S. Government Printing Office: 2006-523-056/40092 Region IV ISSN: 0149-2195